Dissolving microneedles for cutaneous drug and vaccine delivery by Chu, Leonard Yi
DISSOLVING MICRONEEDLES FOR 











Leonard Yi Chu 
 
 
In Partial Fulfillment  
Of the Requirements for the Degree 




Georgia Institute of Technology 
October, 2009 
Copyright © 2009 by Leonard Yi Chu 
 ii 
DISSOLVING MICRONEEDLES FOR 












Dr. Mark Prausnitz, Advisor 
School of Chemical and Biomolecular 
Engineering 
Georgia Institute of Technology 
 
Dr. Niren Murthy 
Department of Biomedical Engineering 
Georgia Institute of Technology 
Dr. Richard Compans 




Dr. Bruce Weniger 
Centers for Disease Control and 
Prevention  (CDC) 
Dr. Valeria Milam 
School of Materials Science and 
Engineering 










My PhD has been a challenging and dramatic one. I am fortunate to work on 
cutting-edge technology in a world-class laboratory. Throughout the course of my 
scientific pursuit in the Drug Delivery Lab, I was given the opportunity to maximize 
my potential to strive for scientific contributions with the highest standard in all 
aspects under the guidance of my PhD advisor, Dr. Mark Prausnitz. Dr. Prausnitz has 
been a great influence on my personal development, professional communications and 
scientific research. His passion, patience, high standard, easy accessibility and 
supervision have enriched my PhD training and prepared me for future challenges. I 
would like to thank my advisor Dr. Mark Prausnitz and my thesis committee members 
Dr. Richard Compans, Dr. Valeria Milam, Dr. Niren Murthy and Dr. Bruce Weniger 
for their involvement, guidance and recommendations for my research and thesis. 
I would like to thank Donna Bondy, our lab’s administrative coordinator. Donna 
is the kindest and the most efficient person I have ever met. My research could not 
have progressed so efficiently and smoothly without her assistance. My research 
could not be completed without daily support from current and past lab members. I 
would like to thank Dr. Seong-O Choi for providing the microneedle master structure, 
which has served as the foundation for the development of microneedles in our lab. I 
would like to thank Samirkumar Patel who has devoted a tremendous amount of time 
ensuring proper functioning of computer hardware and software. I would like to thank 
Dr. Vladimir Zarnitsyn for being a great help in setting up, fixing and maintaining 
laboratory equipment. I would like to thank Samantha Andrews for her advice on 
histology. Samantha has also been a great companion in the conferences we attended 
together. I would like to thank Dr. Sean Sullivan and Dr. Jyoti Gupta for helpful 
 iv
discussion of research and all lab members including Dr. Prerona Chakravarty, Dr. 
Hyo-Jick Choi, Dr. Young Bin Choy, Chris Edens, Dr. Harvinder Gill, Dr. Yasuhiro 
Hiraishi, Josh Hutcheson, Ying Liu, James Norman, Dr. Jason Jiang, Yoo-Chun Kim, 
Dr. Yeu-Chun Kim, Dr. Jeong Woo Lee, Dr. Jung-Hwan Park, Dr. Robyn Schlicher, 
and my undergraduate assistant Ginger Tsai.  
I would like to thank our collaborators from the Emory Vaccine Center led by Dr. 
Richard Compans. I learned a lot and enjoyed working with Dr. Chinglai Yang, Dr. 
Ling Ye and Ke Dong. I also would like to thank Dr. Mark Allen for his guidance as a 
collaborator and his lab members. I especially thank Richard Shafer for his assistance 
and maintenance of the laser facilities. 
I would like to thank all the Institute for Bioengineering and Bioscience (IBB) 
staff and faculty. In particular, I would like to thank Chris Ruffin for his support and 
assistance throughout my entire PhD program. I would like to thank Dr. Laura 
O’Farrell for her mentorship in the Physiological Research Laboratory and Aqua 
Asberry for her guidance in the histology room. I would also like to thank Allen 
Echols for handling packages and maintaining IBB building facilities. I also thank 
Nadia Boguslavsky for the lyophilizer training. In addition to my research life, I 
would like to thank Sally Gerrish for leading our Biotechnology Career Fair 
Committee. 
I would like to thank all my friends’ support and bless from all over the world. I 
would like to thank my string teacher Dr. Sharon Eng for her constant encouragement 
since the inception of high school. I would like to thank my parents and my sister for 
their love and support. I would also like to thank my younger brother, who is currently 
studying at Georgia Tech, for his assistance with my PhD study. 
 
 v
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ...................................................................................... iii 
LIST OF FIGURES AND TABLES ........................................................................ viii 
LIST OF SYMBOLS AND ABBREVIATIONS ..................................................... xiv 
SUMMARY ............................................................................................................ xv 
 
1. INTRODUCTION ................................................................................................. 1 
 
2. BACKGROUND ................................................................................................... 3 
2.1  Drug Delivery ........................................................................................ 3 
2.1.1  Overview of Drug Delivery ....................................................... 3 
2.1.2  Skin Anatomy ............................................................................ 6 
2.1.3  Transdermal Delivery ................................................................ 7 
2.2 Microneedles ....................................................................................... 10 
2.2.1  Development of Microneedles ................................................. 10 
2.2.2  Dissolving Microneedles ......................................................... 12 
2.3 Formulations ....................................................................................... 14 
2.3.1  Pharmaceutical Excipients ....................................................... 14 
2.3.2  Binders .................................................................................... 14 
2.3.3  Fillers ...................................................................................... 16 
2.4 Influenza Vaccine ................................................................................ 18 
2.4.1  Influenza Virus ........................................................................ 18 
2.4.2  Influenza Vaccine Stability ...................................................... 19 
2.4.3  Cold Chain .............................................................................. 20 
2.4.4  Drying Methods ....................................................................... 20 
2.4.5  Stabilizers ................................................................................ 22 
2.5 Immunization with Influenza Vaccine .................................................. 24 
2.5.1  Methods of Immunization ........................................................ 24 
2.5.2  Vaccination in Developing Countries ....................................... 25 
 
3. FABRICATION OF DISSOLVING POLYMER MICRONEEDLES FOR 
CONTROLLED DRUG ENCAPSULATION AND DELIVERY: BUBBLE AND 
PEDESTAL MICRONEEDLE DESIGNS ........................................................... 28 
3.1  Abstract ............................................................................................... 29 
3.2  Introduction ......................................................................................... 30 
3.3  Materials and Methods ......................................................................... 33 
 vi
3.4  Results ................................................................................................. 39 
3.5  Discussion ........................................................................................... 52 
3.6  Conclusions ......................................................................................... 56 
3.7  Acknowledgements .............................................................................. 56 
 
4. RAPID CUTANEOUS DELIVERY USING ARROWHEAD MICRONEEDLES 57 
4.1  Abstract ............................................................................................... 58 
4.2  Introduction ......................................................................................... 59 
4.3  Materials and Methods ......................................................................... 61 
4.4  Results ................................................................................................. 66 
4.5  Discussion ........................................................................................... 74 
4.6  Conclusions ......................................................................................... 77 
4.7  Acknowledgements .............................................................................. 77 
 
5. EVALUATION OF THE STABILITY OF INFLUENZA VACCINE 
ENCAPSULATED IN DISSOLVING MICRONEEDLES ................................... 78 
5.1  Abstract ............................................................................................... 79 
5.2  Introduction ......................................................................................... 80 
5.3  Materials and Methods ......................................................................... 83 
5.4  Results ................................................................................................. 89 
5.5  Discussion ........................................................................................... 97 
5.6  Conclusions ........................................................................................ 100 
5.7  Acknowledgements ............................................................................. 100 
 
6. IMMUNIZATION OF MICE USING ARROWHEAD MICRONEEDLES 
ENCAPSULATING INACTIVATED INFLUENZA VIRUS............................... 101 
6.1  Abstract .............................................................................................. 102 
6.2  Introduction ........................................................................................ 103 
6.3  Materials and Methods ........................................................................ 105 
6.4  Results ................................................................................................ 110 
6.5  Discussion .......................................................................................... 117 
6.6  Conclusions ........................................................................................ 120 
6.7  Acknowledgements ............................................................................. 120 
 
7. DISCUSSION .................................................................................................... 121 
7.1  Mass Fabrication of Microneedles ...................................................... 121 
7.2  Parameters for Uniform and Consistent Microneedle Insertion and  
Delivery to Skin ................................................................................. 123 
 vii
7.3  Formulations for Desired Delivery Profile and Stability of 
Biopharmaceuticals ............................................................................ 124 
7.4  Immunization of Animal Models using Microneedles ......................... 125 
7.5  Future Directions of Dissolving Microneedles .................................... 126 
 
8. CONCLUSIONS ................................................................................................ 128 
8.1  Controlled Drug Loading and Encapsulation in Dissolving Microneedles
........................................................................................................... 128 
8.2  Development of Arrowhead Microneedles for Rapid Cutaneous Delivery
........................................................................................................... 129 
8.3  Stability of Influenza Vaccine Encapsulated in Dissolving Microneedles
........................................................................................................... 130 
8.4  Protection against Lethal Virus Challenge in Immunized Mice using 
Arrowhead Microneedles ................................................................... 131 
 
9. FUTURE DIRECTIONS .................................................................................... 133 
9.1  Optimization of Microneedle Geometry and Design for Clinical 
Application ........................................................................................ 133 
9.2  In Vivo Stability Assessment of Vaccine Encapsulated in Microneedles
........................................................................................................... 134 
9.3  In Vivo Vaccination of Different Animal Models ................................. 134 
 
10. REFERENCES ................................................................................................. 135 
 
 viii




Porcine cadaver skin stained with hemotoxilyn and eosin showing 
stratum corneum, epidermis and dermis. (Bar = 50 µm)……………..…6 
  
Fig. 2.2. Different types of microneedles: (A) Silicon microneedles [63]. (B) 
Metal microneedles [15]. (C) Coated metal microneedles [16]. (D) 
Biodegradable polymer microneedles [19]. (E) Dissolving PVP 
microneedles [22]. (F) Dissolving CMC microneedles [23]……....…..10 
  
Fig. 2.3. A schematic drawing of an influenza virus. HA: hemagglutinin; NA: 
Neuraminidase; M1: Matrix protein; M2: Proton channel. [88]…….....18 
  
Fig. 3.1. Schematic of solid and bubble needle fabrication process. (A) A PDMS 
microneedle mold [140] was filled with drug solution under vacuum; (B) 
Residual drug solution was removed from the surface by a pipette and 
later reused; (C) Drug solution in the mold cavities was dried under 
centrifugation; (D) Drug-free polymer solution was cast onto the mold 
and filled under vacuum; (E1) The polymer solution was either air-dried 
or dried under centrifugation at low speeds; (F1) Dried solid needles 
were peeled off the mold by an adhesive backing; (E2) The polymer 
solution was either physically scraped off the mold surface and then 
air-dried or dried under centrifugation at high speeds; (F2) A backing 
coated with a thin film of concentrated polymer solution was placed on 
top of the mold and then air dried. After drying, the bubble needles were 
peeled off.……………………………………………………………...40 
  
Fig. 3.2. Schematic of pedestal microneedle mold fabrication. (A) A PDMS mold 
was created from a master microneedle structure. (B) An infrared 
laser-cut metal sheet was coated with PDMS; (C) A composite mold was 
formed as the coated metal sheet(s) were placed on top of the PDMS 
mold and cured under heat; (D) Molten polymer was cast onto the 
composite mold by vacuum; (E) After cooling, microneedles with 
pedestal structure were peeled off the composite mold; (F) The pedestal 
microneedles were then used as the master structure for making pedestal 
 ix
PDMS mold replicates (see Fig. 3.1)………………………………….42 
  
Fig. 3.3. Solid and bubble microneedles loaded with model drug localized to the 
tips imaged by bright field microscopy. Top row: Solid needles loaded 
with 1 mg/ml sulforhodamine B encapsulated in (A) 30 wt %; (B) 40 wt 
%; (C) 50 wt % PVA/PVP blends. Bottom row: Bubble needle 
counterparts loaded with 1 mg/ml sulforhodamine B encapsulated in (D) 
30 wt %; (E) 40 wt %; (F) 50 wt % PVA/PVP blends. The arrows 
indicate the location of air bubbles. Bar = 300 µm………………...….44 
  
Fig. 3.4. Percentage delivery of sulforhodamine B over the time during 
microneedle insertion into porcine cadaver skin. Solid lines are for solid 
microneedles and dashed lines are for bubble microneedles made using 
different polymer solution concentrations. Data points represent 
averages of n = 3 replications, with standard deviation bars shown. 
………………………………………………………………………….45 
  
Table 3.1. Drug loading using three different microneedle designs……………....47 
  
Fig. 3.5. Skin insertion depth of three different microneedle structures imaged by 
bright field microscopy. (A) Pyramidal microneedles (base width x base 
depth x needle height: 300 x 300 x 600 µm); (B) Extended pyramidal 
microneedles (300 x 300 x 900 µm) and (C) Pedestal microneedles (340 
x 340 x 900 µm). Corresponding H&E-stained histology cross sectional 
images of insertion sites in porcine cadaver skin: (A1) Pyramidal 
microneedles; (B1) Extended pyramidal microneedles and (C1) Pedestal 
microneedles. The arrows indicate the depth of the microneedle insertion 
track. Bar = 200 µm……………………………………………………49 
  
Fig. 3.6. Microneedle dissolution after insertion into porcine cadaver skin imaged 
by bright field microscopy. Left column shows microneedles uniformly 
loaded with 1 mg/ml sulforhodamine before insertion into skin. (A) 
Pyramidal microneedle; (B) Extended pyramidal microneedle; (C) 
Pedestal microneedle. Right column shows corresponding microneedles 
after a 2 min insertion into skin. The arrows indicate the base of the 
primary 600 µm microneedle structure at its interface with the extended 
pyramidal portion or pedestal portion. Bar = 300 µm………………....50 
  
 x
Fig. 3.7. Microneedle dissolution after insertion into porcine cadaver skin as 
determined by a quantitative mass balance. Loss of micronneedle 
volume was determined based on the amount of sulforhodamine 
encapsulated in microneedles before and after insertion in skin. Data 




Fig. 4.1. Schematic of arrowhead microneedle fabrication process. (A) A PDMS 
mold was filled with the drug of interest by vacuum. (B) Excess drug on 
the mold surface was removed and recycled. (C) Drug loaded in the 
mold cavities was dried by centrifugation. (D) Polymer solution was cast 
into the mold cavities by vacuum. (E) Residual polymer solution was 
spun off by centrifugation. (F) Metal shafts were aligned to the mold 
cavities. (G) The whole device was air-dried at room temperature or 
freeze-dried overnight. After drying, the dried polymer tips connected to 
the metal shafts were removed from the mold. (H) Metal stoppers in 
adjacent to the shafts connected to polymer tips were bent 
down…………………………………..…………………….………….67 
  
Fig. 4.2. Arrowhead microneedles. (A) An array of 5 x 5 arrowhead microneedles 
consisting 600 µm metal shafts capped with 600 µm water-soluble 
PVA/PVP pyramidal tips encapsulating sulforhodamine B (Bar = 1 mm); 
and individual needle’s front view (A1) and side view (A2) (Bar = 300 
µm). (B) An array of 10 x 5 arrowhead microneedles consisting 700 µm 
metal shafts capped with 600 µm water-soluble PVA/Sucrose pyramidal 
tips encapsulating inactivated influenza virus (Bar = 1 mm); and closeup 
view of individual needles (B1) (Bar = 300 µm)……..……………......68 
  
Fig. 4.3. Porcine cadaver skin insertions. En face view of skin imaged by bright 
field (A1) and fluorescence (A2) optics (Bar = 1 mm); Histological cross 
section of a row of microneedle insertion sites (B1) and the 
corresponding fluorescent image of sulforhodamine B released from the 
arrowhead microneedles prior to H&E staining (B2) (Bar = 300 
µm)………………………….………………………………………….69 
  
Fig. 4.4. The effect of arrowhead shaft length on porcine cadaver skin insertion 
depth. (A) A 900 µm needle its corresponding insertion depth under 
 xi
fluorescence (A1) and H&E staining (A2); (B) A 1200 µm needle and its 
corresponding insertion depth under fluorescence (B1) and H&E 
staining (B2); (C) A 1500 µm needle its corresponding insertion depth 
under fluorescence (C1) and H&E staining (C2). Bar = 300 
µm……………………………………………………………………...70 
  
Fig. 4.5. Delivery efficiency of sulforhodamine B in porcine cadaver skin using 
arrowhead microneedles. (A) Dissolution-based delivery over 60 s. (B) 
Delivery facilitated by mechanical shear in seconds…………...….…..71 
  
Fig. 4.6. Deposition of biodegradable PLGA tips using arrowhead microneedles. 
(A) A 1200 µm arrowhead microneedle encapsulating sulforhodamine B; 
(B) The histological cross section of the PLGA microneedle tip 
deposited within the porcine cadaver skin under fluorescent microscopy. 
(Bars = 200 µm)……………………………………………...………...72 
  
Fig. 4.7. Evaluation of arrowhead needle’s safety in human cadaver skin (A) 1200 
µm arrowhead needles with exposed 600 µm shafts, and the 
corresponding insertion (A1); (B) Representative 700 µm arrowhead 
shafts as mimicries of post-insertion needles, and the corresponding 
application of the shafts on the skin stained with tissue marking dye 
(B1); (C) Sharp 700 µm arrowhead shafts with the same aspect-ratio as 
in (B), and the corresponding insertion stained with dye (C1) (Top Row: 
Bar = 300 µm; Bottom Row: Bar = 1 mm)…...………………..………73 
  
Fig. 5.1. Dissolving microneedles encapsulating inactivated influenza virus. (A) A 
10 x 10 microneedle array. (B) Side view of microneedles……....……89 
  
Fig. 5.2. Effect of microneedle fabrication drying process on HA activity. Day 0 
indicates the dried microneedles immediately after fabrication. Day 5 
indicates the microneedles stored in sealed containers with desiccants at 
25°C over five days. (N = 4)…..…………………………………….....91 
  
Fig. 5.3. Effect of formulation on HA activity. Each bar shows a different 
formulation composition consisting of PVA and/or sucrose dissolved in 
DI water. (N = 4)….……………………………………………………92 
  
Fig. 5.4. Comparison of the long-term stability of unprocessed vaccine solutions 
 xii
versus dried microneedle vaccine samples based on HA potency under 
different temperatures. MN indicates the processed vaccine encapsulated 
within the microneedles. WET indicates the unprocessed vaccine in 
solution. (N≥3)………………………..………………………………..93 
  
Fig. 5.5. Comparison of the long-term stability of dried microneedle vaccine 
samples stored under different packaging condition. N: Open containers 
without any control of humidity. D: Sealed containers with controlled 
humidity by desiccants. DV: Sealed containers filled with nitrogen gas 
and with controlled humidity by desiccants. (N≥3)…….……………...94 
  
Fig. 5.6. Evaluation of vaccine stability over 2 weeks using capture ELISA. Left: 
Microneedle samples (MN) containing encapsulated vaccine stored at 4°C, 
25°C, 37°C and 45°C. Right: unprocessed vaccine solution (C) stored at 
4°C (control), 25°C, 37°C and 45°C. (N≥3)…………………………….95 
  
Fig. 5.7. Images of electron microscopy of negatively stained inactivated 
influenza virus particles stored at different temperatures. (A) The 
encapsulated virus particles dissolved off the microneedles stored at 4°C, 
25°C, 37°C and 45°C maintained intact particle morphology with visible 
lipid bilayer structures. (B) The unprocessed virus particles stored at 4°C 
kept an intact morphology while all other unprocessed virus particles 
stored at elevated temperatures showed ruptured structures or absent 
lipid bilayers……………………........................................................…96 
  
Fig. 6.1. Single immunization timeline. Week 0: Mice (six per group) were 
immunized by intramuscular injection and cutaneous microneedle 
insertion. Week 2, 3 and 4:  Blood samples were collected 
retro-orbitally for antibody serum and HAI analyses. Week 4: After 
collecting the blood samples, the mice were challenged by 
mouse-adapted PR8 and WSN viruses. Week 6: The mice were 
sacrificed and additional blood samples were collected...……………107 
  
Fig. 6.2. An array of 10 x 5 arrowhead microneedles: (A) Encapsulating IIV; (B) 
Side view; (C) Encapsulating sulforhodamine B; And (D) insertion into 
mouse skin in vivo. Bar = 1 mm…………..………………………….111 
  
Fig. 6.3. Comparison of induced antibody responses 4 weeks after immunization. 
 xiii
Eight groups of mice were immunized, six mice per group. Mice were 
immunized by microneedles (MN), intramuscular injection (IM), 
intramuscular injection of IIV dissolved off the microneedles (Redis) 
and intramuscular injection of PBS (control). (A) The serum antibody 
levels against HA proteins were measured by ELISA. (B) The HAI 
activity was determined by the maximum dilution of serum samples that 
inhibited hemagglutination……………………………………...…….113 
  
Fig. 6.4. Change of mouse weight over two weeks after lethal challenges. (A) 
Four groups were challenged by homologous virus strain (PR8); (B) The 
other four groups were challenged by heterologous virus strain (WSN). 
Each group contained 6 mice. A dose of 10 µg IIV was given to each 
mouse. Mice were immunized by microneedles (MN), intramuscular 
injection of IIV (IM), intramuscular injection of IIV dissolved off the 
microneedles (Redis) and intramuscular injection of PBS (control). Mice 
were sacrificed when the body weight lost more than 30 
%...........................................................................................................115 
  
Fig. 6.5. Survival rate of mice after lethal challenges. Mice were monitored for 
additional two weeks of their protection against infection of (A) 
homologous strain (PR8), (B) heterologous strain (WSN). Mice were 
immunized with a dose of 10 µg IIV by microneedles (MN), 
intramuscular injection (IM), intramuscular injection of IIV dissolved off 
the microneedles (Redis), and intramuscular injection of PBS (control). 





































analysis of variance 
bicinchoninic acid 
bovine serum albumin 
deionized 
enzyme-linked immunosorbent assay 
hemagglutinin/hemagglutination 
hemagglutination inhibition 
a subtype of influenza A virus 
hematoxylin and eosin 
institutional animal care and use committee 
immunoglobulin G 
inactivated influenza virus 
infrared 
lethal dose for 50% to die 
microneedle 
neuraminidase 
optimal cutting temperature 




a strain of H1N1 influenza virus (A/Puerto Rico/8/34)  
polyvinyl alcohol 
polyvinylpyrrolidone 
red blood cell 
polymeric photoresist epoxy 
transmission electron microscope 







Currently, biopharmaceuticals including vaccines, proteins, and DNA are 
delivered almost exclusively through the parenteral route using hypodermic needles. 
However, injection by hypodermic needles generates pain and causes bleeding. The 
needle itself poses risk of needle-stick injury. Disposal of these needles also produces 
biohazardous sharp waste. An alternative delivery tool called microneedles may solve 
these issues. Ideally, a skin delivery system should (i) deliver a broad range of 
therapeutics including chemical compounds, macromolecules and biologics, (ii) have 
a controlled dose with high bioavailability, (iii) be safe, (iv) be simple to use, and (v) 
be inexpensive. Current microneedle systems have addressed some of the 
requirements described above, but further characterizations and improvements are still 
needed. This project focused on one type of microneedles in which the needle tips 
dissolve upon insertion into the skin. The goal was to design and optimize dissolving 
microneedle fabrication processes for efficient drug and vaccine delivery to skin. This 
project also covered the formulation design and drying process for optimal vaccine 
stability. Finally, the microneedles were tested in vivo for influenza immunization. 
The first goal was to develop new dissolving microneedle design and fabrication 
process for controlled drug loading, drug encapsulation and delivery with enhanced 
bioavailability in the skin. Due to the use of aqueous-based excipients for microneedle 
matrix, undesired drug diffusion within microneedles could occur during fabrication. 
To achieve high bioavailability, novel fabrication methods were developed to control 
drug diffusion by localizing the drug only in the microneedle tips. Deeper 
microneedle insertion was achieved by incorporating a pedestal for enhanced 
bioavailability. 
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The second part of the project focused on developing a new dissolving 
microneedle system called arrowhead microneedles. The key advantages of 
arrowhead microneedles include short administration time on the scale of seconds, 
full insertion of the needle tips into the skin and leaving no biohazardous sharp waste 
after use. Arrowhead microneedles could fully deposit the tips containing drug within 
the skin for expedited delivery. This rapid delivery could be achieved by two 
mechanisms: One relied on gradual dissolution of the tips within the skin; another one 
used mechanical force to separate the tips from the shafts. Upon insertion, the sharp 
microneedle tips were embedded within the skin while the dull shafts and backing 
could be quickly removed and disposed without concerns for needle stick injury and 
generation of biohazardous sharp waste. 
After optimizing dissolving microneedle fabrication, structural design and 
delivery, we wanted to ensure the encapsulated molecules within microneedles 
remained stable. We encapsulated inactivated influenza virus within the dissolving 
microneedles made of a novel formulation consisting of polyvinyl alcohol and sucrose. 
The encapsulated vaccine samples were stored at 4°C, 25°C, 37°C, and 45°C under 
different packaging conditions. The results showed that the encapsulated vaccine 
maintained its hemagglutination potency, antigenic property and virus particle 
morphology over extended periods of time while the unprocessed vaccine suspended 
in solution lost virtually all hemagglutination activities and morphology within a few 
days. According to the results, we concluded that solid-state encapsulation of the 
vaccine in dissolving microneedles provided more potent stability over liquid-state 
vaccine.   
Finally, based on all the optimizations of dissolving microneedles described in 
previous chapters, arrowhead microneedles encapsulating inactivated influenza virus 
vaccine were evaluated in vivo. Mice were immunized with a single dose using 
 xvii
arrowhead microneedles. The results showed that the immune responses as measured 
by virus-specific IgG levels 4 weeks after vaccination were statistically equivalent to 
the intramuscular injection of the same vaccine dose using hypodermic needles. The 
immunized mice were protected from lethal virus challenge. 
We envision the newly developed dissolving microneedle system can be a safe, 
patient compliant, easy-to-use and self-administered method for rapid drug and 





Skin offers an attractive site for drug and vaccine delivery. Being the largest 
organ of the body, skin is easily accessible and allows both local and systemic 
treatment. Unlike the oral administration, transdermal delivery bypasses poor 
absorption, enzymatic degradation in the gastro-intestinal track and metabolism in the 
liver [1, 2]. Transdermal drug delivery is mainly hampered by the presence of stratum 
corneum, the outermost layer of the skin. This tissue barrier prevents molecules larger 
than about 500 Da or hydrophilic drugs from entering into the body [3]. To deliver 
macromolecules or skin impermeable compounds effectively across the skin, the 
stratum corneum has to be altered, removed or disrupted.   
The most commonly used tool for delivering therapeutics by injection is 
hypodermic needles. Although hypodermic needles can overcome the skin barriers 
effectively, these needles create pain, cause bleeding and generate sharp biohazardous 
waste. These issues decrease the willingness of patients to receive medication. 
Extreme cases of such fear can create needle phobia [4-6]. Incidents of needle-stick 
injury are common. Disposal of the needles can be costly and environmentally 
burdensome. Developing countries in particular have high incidence of needle misuse 
[7]. Due to lack of medical resources, sharing and reuse of needles are commonly 
seen. Such mishandling of needles promotes the transmission of blood-born 
pathogens including hepatitis B, HIV and other diseases.     
To address the issues and limitations of hypodermic needles, we developed an 
alternative delivery tool called microneedles. Microneedles are micron-size needles 
that disrupt stratum corneum in a minimally invasive manner [8, 9]. The needles 
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target the epidermis and superficial dermis of the skin where abundant immune cells 
are present while keeping the deeper tissue undamaged. Some methods of drug 
delivery using microneedles have already been developed. For example, the skin can 
first be treated with microneedles followed by drug application at the treatment site 
[10-14]. Alternatively, the drug can be coated onto solid microneedles [15-17] or 
encapsulated within biodegradable [18, 19] or dissolving microneedles [20-23]. The 
drug is then released within the skin upon insertion. 
The primary choice of microneedle in this project is dissolving microneedle.  
Dissolving microneedles are made of water-soluble excipients. The molecules of 
interest are encapsulated within the needles. Upon insertion, the microneedles 
dissolve and then release the encapsulated molecules within the skin. To study drug 
and vaccine delivery to skin using dissolving microneedles, the project covers four 
main areas: 
1.  To optimize the fabrication process of dissolving microneedles with controlled 
drug encapsulation, enhanced drug loading capacity with minimal drug wastage, 
and more complete insertion of the needle tips into skin for improved 
bioavailability.  
2.  To develop a novel microneedle system that requires a short administration time, 
results in complete insertion of the needle tips, and produces no sharp waste after 
use. 
3. To study the stability of encapsulated vaccines in microneedles during 
microneedle processing and post-processing storage under different temperatures 
and different packaging conditions over extended periods of time. 
4.  To immunize mice using the newly developed microneedle system and evaluate 





2.1  Drug Delivery 
 
2.1.1  Overview of Drug Delivery 
 
The U.S. annual sales of advanced drug delivery systems are approaching $20 
billion and are growing rapidly [1, 24]. As new drugs and biopharmaceuticals 
continue to emerge, development of drug delivery systems for achieving optimal 
therapeutic effects is receiving increasing attention in the pharmaceutical, 
biotechnology and medical community.  
Drug delivery system is a broad term for technology that sends drugs to the 
appropriate target site for generating therapeutically desirable effects. The technology 
can be largely divided into two categories: macro delivery systems that use medical 
devices, tools or various dosage forms to deliver drugs into the body; and particulate 
delivery systems that use micro- and nano-vehicles to encapsulate drugs and provide 
functionalities for delivery at cellular and molecular level. The scope of the thesis 
primarily focuses on the macro delivery systems, although the microneedles 
themselves are of micron dimensions. 
Scientists have been exploring various delivery systems that send drugs into the 
body via different routes to achieve local and systemic prevention and treatment of 
diseases. Each route of delivery has its own advantages and disadvantages. Some 
methods of delivery are more invasive than the other. Oral administration of small 
molecules by swallowing oral dosage forms is the most common practice of medical 
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treatment due to its noninvasive nature. Because of the varying degree of absorption, 
metabolism and excretion from the body, a great deal of effort has been spent on 
controlled release of drug to achieve sustaining drug levels in the desirable therapeutic 
range. However, biopharmaceuticals taken orally face major challenges including 
poor absorption and enzymatic degradation in the GI track, and metabolism in the 
liver [1, 2]. To avoid these obstacles, biopharmaceuticals in particular are delivered 
through other routes including pulmonary, parenteral and transdermal. 
Pulmonary delivery is another example of a noninvasive delivery method. 
Delivering drugs and biopharmaceuticals to the lung has been used to treat respiratory 
diseases such as asthma [25, 26] and cystic fibrosis [27]. The therapeutic effect of 
pulmonary delivery can be local in the upper respiratory tract and the lung or systemic 
if absorbed into the alveoli. The main advantage of delivery through the lung is the 
large absorption surface area with thin tissue lining and limited presence of 
proteolytic enzymes [28, 29]. One of the greatest challenges for pulmonary delivery is 
the reproducibility of delivery and delivery efficiency. The delivery efficiency 
typically lies between 20-50% of the drug administered to the lung [30]. 
The parenteral route is the most direct way of getting molecules into the body 
circulation. Injection of therapeutics through the skin into the blood stream or 
surrounding tissues produces high delivery efficiency within very a short 
administration time. This method of delivery is accomplished almost exclusively by 
needle-syringe system. However, the system’s sharp hypodermic needle generates 
bleeding and pain, leading to low patient compliance and needle phobia, a symptom 
characterized by frightening reaction which includes plunging blood pressure and 
fainting [4-6]. 
Sending drugs into the body circulation while avoiding the first pass effect, skin 
offers an attractive option. Being the largest organ of the body, skin is very accessible 
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for local and systemic treatment. However, due to the presence of the outermost 
dominant barrier of the skin, the stratum corneum, only a limited number of drugs are 
able to pass through the skin passively. These transdermal drugs are subject to 
constraints including molecular size less than about 500 Da and octanol-water 
partition coefficients that highly favor lipids and small required dose up to miligrams 
[31]. To deliver chemical compounds or macromolecules beyond the constraints 
across the skin, chemical or physical methods that alter or remove the stratum 
corneum are required. Various methods and devices have been designed to facilitate 
the transport of molecules across the skin non-invasively or with minimal 
invasiveness. More details will be discussed in the following sections. 
Other delivery routes include nose, vagina, eye, etc. These delivery routes are 
less commonly used due to accessibility. However, they are important and effective 
routes for local treatment of diseases. 
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Fig. 2.1. Porcine cadaver skin stained with hemotoxilyn and eosin showing stratum 
corneum, epidermis and dermis. (Bar= 50 µm) 
 
Skin is comprised of three distinct layers: stratum corneum, viable epidermis and 
dermis. Stratum corneum is the topmost layer of the skin. This layer consists of dead 
keratinocytes, also known as corneocytes, forming a 10~20 µm thick stack. Stratum 
corneum serves as the dominant barrier in limiting the passage of molecules from 
entering the skin. The structural arrangement of corneocytes in lipid bilayers is often 
described as the bricks and mortar of a brick wall [32]. Viable epidermis is the next 
deeper section of the skin. It is roughly 0.1 mm thick mainly consists of keratinocytes. 
The keratinocytes linked by desmosomes offer both structural strength to epidermis 
and resistance for passage of molecules across the epidermis [33, 34]. Beneath the 
epidermis layer is a 2 to 3 mm dermis layer containing capillaries, nerves, hair 
follicles and sweat glands. Below dermis is called the hypodermis where fat is the 
primary constituent [35]. 





including Langerhans cells, CD8+ and CD4+ T lymphocytes, mast cells and 
macrophages [36-39]. Langerhans cells, comprising about a quarter of the skin 
surface area, are believed to play a major role in cutaneous immunization upon 
stimulation [40]. Dermal dendritic cells, upon activation, bring antigen from the skin 
to draining lymph nodes and present the antigen to T helper lymphocytes for 
subsequent immune responses [35]. However, the specific mechanisms of the 
resulting immune response remain unclear. 
 
2.1.3  Transdermal Delivery 
 
Transdermal delivery represents an attractive alternative to needle-syringe 
system for several reasons. Transdermal delivery is a noninvasive method that sends 
drugs directly to the body circulation without going through the first pass effect. 
Earlier generation of transdermal delivery involves liquid spray, gel, topical 
formulation or patch, which serve as the reservoir for extended release of drugs into 
the skin. Examples of such products include testosterone gels, estradiol spray and 
contraceptive patches. The limitation of topical application lies upon the barrier 
function of the stratum corneum which permits only molecular size less than 
approximately 500 Da and highly lipophilic drugs to enter [3]. The new generation of 
transdermal delivery seeks to overcome the barrier function of stratum corneum by 
adding chemical enhancers that reversely alter the stratum corneum or introduce 
driving force to facilitate transport of molecules across the skin [41]. Chemical 
enhancers disrupt the organization of stratum corneum lipid bilayer by inserting 
amphiphilic molecules [42, 43]. Other chemical enhancers use supramolecular 
structures such as liposomes and denrimers to increase skin permeability and drug 
partition to the skin. More recently, biochemical enhancers use peptides to enhance 
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the skin permeability by forming transient pores in the stratum corneum [44, 45]. 
Iontophoresis uses a different approach that enhances transdermal delivery by 
applying an electrical current to drive molecules across the skin barrier [46, 47]. The 
delivery rate scales with the electrical current. Therefore, the drug release profile and 
dosing can be controlled for small molecules or larger highly charged molecules 
delivery [48]. Applications of iontophoresis include delivery of lidocaine and fentanyl 
for local anesthesia [49, 50] and pilocarpine to induce sweat for the diagnosis of 
cystic fibrosis [51, 52]. In addition to enhance skin permeation by electrical means, 
ultrasound, an oscillating pressure wave also has shown to enhance the flux of small 
molecules like lidocaine [53] and large biomolecules like insulin, heparin and vaccine 
[54, 55]. Ultrasound promotes the transdermal delivery by generating cavitation 
resulting from the oscillation and collapse of bubbles at the skin surface.  
Stratum corneum can also be removed by physical means including thermal 
ablation, tape stripping, microdermabrasion using sandpaper and device. Thermal 
ablation uses heat to selectively perforate skin for microseconds to milliseconds 
without damaging deeper tissue [3, 56]. Animal studies have shown the thermal 
ablation successfully delivered human growth hormone and interferon alpha-2b into 
the skin [57, 58]. A repetitive stripping of stratum corneum using adhesive tape has 
shown to enhance the permeability of macromolecules such as low molecular weight 
heparin across the skin [59]. Similarly, abrasion using sandpaper against the skin has 
also shown to remove stratum corneum effectively for enhanced transdermal drug and 
vaccine delivery [60, 61]. Recently, studies have demonstrated that physical methods 
can remove stratum corneum selectively and completely using a microdermabrasion 
device in a more controlled and precise manner for an enhanced skin permeability 
[62].  
Another physical method which does not involve removal, rather perforation of 
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stratum corenum is the use of microneedles. Microneedles are minimally invasive 
transdermal delivery tools that create micron-size channels in the skin, thereby 
allowing a wide range of drugs and biomolecules to pass through the skin. Details 
about microneedles are discussed in the next section. 
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2.2  Microneedles 
 
2.2.1  Development of Microneedles 
 
 
Fig. 2.2. Different types of microneedles: (A) Silicon microneedles [63]. (B) Metal 
microneedles [15]. (C) Coated metal microneedles [16]. (D) Biodegradable polymer 
microneedles [19]. (E) Dissolving PVP microneedles [22]. (F) Dissolving CMC 
microneedles [23]. 
 
Microneedles are arrays of microscopic needles that enable active delivery of a 
wide range of molecules into the skin. The concept of microneedles is a combination 
of hypodermic needles and transdermal patches. Microneedles contain sharp tips that 
disrupt the stratum corneum but are not long enough to cause damage to the deeper 
tissue. Microneedles are also assembled and applied like a patch onto skin as a 
minimally invasive delivery method. Studies have shown that the microneedle 
insertion on human subjects can have minimal sensation of pain [64, 65].  
There are several types of microneedles that adopt different mechanisms of 
A B C 
D E F 
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delivery. Solid microneedles can be used to enhance skin permeation by creating 
holes for subsequent drug application on the microneedle-treated skin site [10-14, 66]. 
Drugs can also be directly coated on the solid microneedles and are released within 
the skin upon insertion [15-17]. Hollow microneedles, similar to hypodermic needles 
except the needles are fabricated into micron size, contain channels for drug solution 
to flow through. In this project, solid microneedles are of primary interest; hollow 
microneedles will not be mentioned further, because they are more difficult to make 
and use. 
Solid microneedles were first introduced as microfabricated needles etched out 
of a silicon substrate. Those needles are extremely sharp with radius of curvature < 1 
µm which facilitates piercing into the skin [63, 67]. Since silicon is brittle, not 
biodegradable and not proven biocompatible in the human body [68], any fracture of 
silicon microneedles in the skin may raise health concerns. Metal has been used as an 
alternative material to silicon for microneedle fabrication [69-71]. Needles made of 
metals are mechanically robust, and some are known to be biocompatible [72], 
although metal needle breakage in the skin is still undesirable. Lasers can pattern 
microneedles on metal sheets into rows of in-plane needles or arrays of needles that 
will be bent out-of-plane. A wide range of molecules from chemical compounds to 
biomolecules can be coated onto the needle substrate [15, 73]. Since metal needles are 
made sharp and not degradable, for safety reason proper disposal of the sharp waste is 
required. 
To address the non-biodegradable disposal problem, biodegradable polymer 
microneedles have been introduced. These polymer microneedles are made by 
molding at high temperature. The drugs of interest are encapsulated within, instead of 
coated on, the biodegradable needles. Upon insertion, the polymer slowly degrades 
within the skin for controlled release [19, 74]. Needle fracture within the skin would 
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not pose a concern since the chosen polymers used for microneedle fabrication are 
biodegradable into safe degradation products and will ultimately be excreted from the 
body. However, fabrication of biodegradable polymer microneedles requires high 
temperature, which can damage the encapsulated heat-sensitive drugs and 
biomolecules. In addition, biodegradable polymer microneedles (e.g. poly (lactic) acid) 
require weeks to months to degrade. Continuous wearing of biodegradable 
microneedle patch for months is unappealing. Nevertheless, biodegradable polymer 
microneedles are expected to be safe to administer and pose little environmental waste 
hazard. 
 
2.2.2  Dissolving Microneedles 
 
Another type of polymer microneedles is made entirely of water-soluble 
excipients. These water-soluble microneedles, also known as dissolving microneedles, 
dissolve rapidly upon insertion into skin, leaving no biohazardous sharp waste. Since 
drugs or biomolecules are encapsulated within the water-soluble matrix, the drug 
release profile largely depends on the dissolution rate of the microneedles within the 
skin. There are a number of ways to fabricate dissolving microneedles using different 
materials and adopting different fabrication techniques. Molten-based dissolving 
microneedles are made by melting excipients at an elevated temperature and then 
cooling to form a solid structure [20, 75]. Dissolving polymer microneedles can also 
be made by drying long-chain polymer solution using desiccants, centrifugal force or 
ventilation [21, 23, 76]. These fabrication processes are carried out at ambient 
temperature, which avoids thermal damage to the encapsulated drugs or biomolecules. 
Other method of fabricating dissolving microneedles involves the use of UV light to 
polymerize monomers into polymers in the absence of water or other solvents [22].  
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The main advantage of dissolving microneedles is the safety of use.  Because 
the sharp needle tips dissolve and disappear upon insertion, there are no concerns for 
fracture of the needle tips within the skin, and reuse or sharing of the needles among 
patients. However, the key limitation for dissolving microneedles is their mechanical 
properties. High-aspect ratio structure increases the chance of premature needle 
fracture upon insertion into the skin [18] whereas low-aspect ratio needles may not 
insert into the skin completely [23]. To address the limitations of microneedles in 
general, this thesis devotes two chapters to discuss new findings regarding the 
improvements on dissolving microneedle design, fabrication and delivery.  
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2.3  Formulations 
 
2.3.1  Pharmaceutical Excipients 
 
An excipient is an inactive ingredient added to the active ingredients of a 
medication to aid the delivery. For example, many medications in powder form are 
difficult to administer orally, exicipients can bulk up the size of the medications into 
oral dosage form for the ease of dosing, handling and swallowing. In some cases, the 
medications may not be easily absorbed or be able to reach the target site in the body. 
In this case, excipients can facilitate absorption, offer protection against 
environmental change and control release profile of drugs in the body. The 
classification of excipients into functional categories depends on the roles they serve 
in the given route of administration and the form of medication. Due to the presence 
of a vast number of excipients and functionalities, the following sections only address 
excipients and functionalities that pertain to this project’s microneedle fabrication and 
design. 
 
2.3.2  Binders 
 
The term “binder” is used to describe an excipient that holds the active and 
inactive ingredients together. This is common in pharmaceutical oral dosage forms in 
which the binders help the formation of tablets or granules for the ease of handling 
and ingestion. Another principle role of binders is to offer mechanical strength to the 
dosage form. Formulations used for microneedle coating solution and dissolving 
microneedle fabrication contain binders such as carboxymethyl cellulose, dextrin and 
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xanthan gum as the mechanical support [21, 23, 73]. For coated microneedles, long 
chain polymers such as methyl cellulose, hydroxypropyl cellulose, polyethylene 
glycol and polyvinyl alcohol also serve as the viscosity enhancers for successful 
control of coating and dosing [15]. 
In this project, the chosen binder for making dissolving microneedles is 
polyvinyl alcohol (PVA). PVA is a water soluble synthetic polymer. Its physical 
characteristics depend on the degree of hydrolysis of polyvinyl acetate during 
manufacturing. In general, the polymer is considered harmless. It has been used 
widely since the 1930s in industrial, commercial, pharmaceutical and food 
applications. Moreover, it is approved in several medical applications including 
transdermal delivery, oral administration and ophthalmic solution such as synthetic 
tears. PVA is included in the FDA Inactive Ingredient Guide [77] for topical 
application, transdermal delivery, intramuscular injection, ophthalmic solution, and 
oral tablet. The solubility in aqueous solution and biodegradability of PVA make this 
polymer an excellent candidate for formulation preparation and medical device 
fabrication.  
Disposal of medical parts made of PVA is environmentally harmless. Several 
microorganisms with ubiquitous presence in artificial and natural environments have 
shown to degrade PVA by enzymatic processes [78]. The absorption, distribution and 
excretion of orally administered PVA (MW < 50,000) in rats have also been evaluated. 
Studies found that greater than 98% of ingested PVA was recovered in feces within 
48 h, less than 0.2% was found in urine and accumulation in the tissue was not 
detectable [79]. Toxicological studies of oral administration including acute toxicity, 
genotoxicity and reproductive toxicity all have shown that PVA is relatively harmless 
even at relatively high doses [80-83].   
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2.3.3  Fillers 
 
Fillers in pharamaceutical terms means the excipients used for bulking up the 
size and providing the shape to a dosage form. The proper size and shape is important 
for the convenience of patients to handle the medication. Fillers also provide proper 
filling of the microneedle mold during dissolving microneedle fabrication. Fillers are 
generally very water soluble; they can be prepared into highly concentrated solution 
without much viscosity contraint. Therefore, fillers offer a complementary role to the 
binders when the formulated solution is approaching its solubility and viscosity limit. 
Fillers used in this project include polyvinylpyrrolidone (PVP) and sugar molecules 
(sucrose, trehalose, maltodextrin).  
PVP is a water-soluble polymer made from monomer N-vinylpyrrolidone.  It 
readily dissolves in water. It is a poor viscosity enhancer; therefore it can be prepared 
into highly concentrated polymer solution. PVP has been used in a number of 
industries including pharmaceuticals, food, beverage, cosmetic, toiletry and 
photography [84]. According to the FDA Inactive Ingredient Guide [77], PVP is used 
in transdermal delivery, oral dosage forms, inhalation, and ophthalmic solution. The 
toxicity of PVP K-30 (average MW ~ 40,000) has been evaluated in rats by topical 
application to the skin, inhalation and oral administration. PVP is considered safe and 
no significant toxic effects were reported [85]. However, there have been some 
concerns for PVP retention in the body. Studies have shown that injection of high 
dose of PVP with molecular weight > 100,000 can cause labeled PVP thesaurosis or 
PVP storage disease [86]. Injection of PVP with molecular weight < 20,000 resulted 
in better body clearance; greater than 90% is excreted in the urine and feces within 48 
h and only less than 1% PVP is left at the injection site [87]. 
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Sugars are essential to human nutrition.  This project used three types of sugar 
as the fillers for dissolving microneedle fabrication, namely sucrose, trehalose and 
maltodextrin. Sucrose is a disaccharide of glucose and fructose. Trehalose is also a 
disaccharide formed by an α, α-1, 1-glucoside bond between two α-glucose units. 
Maltodextrin is a short chained soluble starch sugar made from hydrolysis of starch. 
All three sugars are absorbed and metabolized into glucose, the primary energy source 
for cells and proper function of human body. Sucrose and Trehalose are known for 
their high water retention capabilities. In addition to serving as additives in the food 
industry, these sugars have been used in many pharmaceutical formulations. For 
example, bevacizumab, marketed as Avastin, contains α,α-trehalose dihydrate. 
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2.4  Influenza Vaccine 
 




Fig. 2.3. A schematic drawing of an influenza virus. HA: hemagglutinin; NA: 
Neuraminidase; M1: Matrix protein; M2: Proton channel. [88]   
 
Influenza spreads rapidly and imposes considerable burdens in economy and 
health care cost. The annual epidemics are thought to cause three to five million cases 
of severe illness and 250,000 ~ 500,000 deaths annually around the globe [89]. Most 
deaths currently associated with influenza in industrialized countries occur among the 
elderly over 65. Not much is known about the impact of influenza in the developing 
world. However, there are cases indicating that influenza outbreaks can result in 
massive deaths within a short period of time [89]. 
Influenza viruses are divided into three groups, A, B and C. The surface of 
influenza viruses is coated with spike-like antigens, namely hemagglutinin and 
neuraminidase. Due to frequent minor genetic changes in the viruses, known as the 
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antigenic drift, annual reformulation of vaccines is necessary to fight specifically 
against influenza subtypes [90]. 
Various influenza vaccines have been used for more than 60 years such as 
inactivated vaccines. A more recently used influenza vaccine includes live, attenuated 
vaccines. The inactivated whole-virus form is the chosen vaccine for this project. The 
amount of vaccine given to patients typically is one dose; equivalent to 15 µg of 
vaccine [91]. For trivalent vaccine containing three strains, 45 µg of antigen is given 
[92].   
 
2.4.2  Influenza Vaccine Stability 
 
Almost all influenza vaccine today is formulated into liquid. The presence of 
dynamic chemical and physical interaction in aqueous solution leads to a limited 
life-time of vaccine stability. There are a number of factors that can be used to 
determine the stability of influenza vaccine, including hemagglutinin content, 
presence of neuraminidase, pH and visual appearance of the vaccine solution [93]. 
Hemagglutination potency is a sensitive parameter for stability determination [94]. 
Long term stability studies are typically carried out by following the ICH guidelines 
[95, 96]. Due to temperature sensitivity of inactivated influenza vaccine, either 
elevated temperature or freezing can damage and denature the vaccine antigens [93, 
97, 98]. Therefore, inactivated influenza vaccine must be stored at temperature from 
2°C to 8°C for maintenance of its optimal quality. This narrow temperature range 




2.4.3  Cold Chain 
 
Cold chain is defined as a series of temperature controls during transport, storage 
and distribution of shipments from the site of manufacturing to the final destination of 
delivery. In many cases, cold chain involves constant monitoring of the goods and 
requires special packaging. For example, vaccine vial monitors (VVMs), a type of 
time-temperature indicator, prevent the usage of vaccines that have had prolonged 
exposure to elevated temperature. For influenza vaccines, as well as many other drugs 
and biopharmaceuticals, the temperature is typically set between 2 °C to 8 °C (-30°C 
to 5°C for some) [99]. Cold chain is critical for transport of vaccines to distant regions 
with hot climates, particularly in the developing world. Disruption of cold chain can 
lead to mass vaccine wastage. Historically there were cases in which the cold chain 
was disrupted by wars. Vaccine wastage may also result from other causes such as the 
expiration of vaccine or thermal damage (including freezing) due to improper 
handling or equipment failures in the cold chain [100]. 
 
2.4.4  Drying Methods 
 
Ideally, influenza vaccines that are stable at freezing condition, room 
temperature, and even transient elevated temperatures would reduce the reliance on 
cold chain. In an attempt to produce a more stabilized vaccine formulation, one 
method is to convert liquid vaccine into dry powder form. The methods of drying 
biopharmaceuticals including proteins, vaccines and macromolecules for enhanced 
stability have already been established and practiced. Much evidence has supported 
the general statement that biopharmaceuticals in a dry state are more stable than in a 
liquid state. The reasons for better stability in solid state can possibly be attributed to 
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less mobility and vibration of the molecules, absence of actively mobile degradative 
enzymes and hydrolysis. However, the process of drying (and/or freezing) may induce 
stress to the structural integrity, thereby changing the conformation and thus the 
activity of the molecules. 
There are a number of drying methods; each has its own advantages and 
disadvantages. Although the quality of drying method also depends on the vaccine 
formulation, the details of incorporating stabilizers in the formulation for drying will 
be discussed in the next section. When given vaccination using a needle-syringe 
system, dried powder vaccines need to be reconstituted into solution. On the other 
hand, dried powder vaccines can be used directly in alternative delivery methods 
including nasal, pulmonary or epidermal delivery by means of inhalation or 
PowderJet-injection [101, 102]. In this project, two drying methods have been 
adopted. These methods are described below: 
Freeze drying, also known as lyophilization, is a process involves freezing of 
sample and then removing solvent (most cases are water) by sublimation (direct 
transition from solid to gas phase) under high vacuum. Generally, lyophilization is the 
preferred method of drying biopharmaceuticals [103]. Lyophilization can be divided 
into three stages: freezing, primary drying and secondary drying [104]. The rate of 
freezing is critical; generally it is preferred to freeze the sample instantly instead of 
gradual cooling. Slow freezing can increase the chance of protein degradation due to 
prolonged exposure to phase separation. Slow freezing also encourages biomolecular 
degradation as the solute becomes more and more concentrated [105]. The next stage 
is primary drying. Primary drying is a process that removes water from the frozen 
sample by sublimation. During the drying cycle, the ice is transferred from the sample 
to the condenser where the pressure is well below the vapor pressure of ice. Majority 
of water is removed by the end of the primary drying cycle. Next, the secondary 
 22
drying further reduces the residual moisture left from the primary drying to achieve a 
moisture level less than 1%. During the secondary drying process, more energy is 
required to remove the residual water by desorption. Thus, this drying process 
typically operates at a much higher temperature than the primary drying.  
Other speedier drying processes other than air-ventilation that are applicable to 
drying microneedles are vacuum drying and desiccation. Vacuum drying is a process 
of reducing the pressure such that the boiling point of water becomes lower than the 
sample temperature. Desiccation involves drying samples with a hygroscopic 
substance such as dry silica gel or anhydrous caustic soda (desiccants) in a sealed 
container (desiccator). The advantages of these two processes are low cost and can be 
carried out at ambient temperature without subjecting to heat or freezing stress. 
 
2.4.5  Stabilizers  
 
Solely drying vaccines into solid state does not guarantee the long-term stability, 
even if the drying process itself does not cause damage to the vaccines. Vaccine 
formulation also plays a critical role in long-term stability. This project used trehalose 
and sucrose as the primary stabilizers for lyophilizing the encapsulated influenza 
vaccine. Numerous studies have shown that sugars offer stability to proteins 
[106-109], liposomes and viruses [110, 111] during drying and subsequent storage. 
When properly dried with sugars, the molecules become embedded in the amorphous 
sugar in its glassy state. Studies have offered several explanations to the enhanced 
stability of biopharmaceuticals in sugar glass. The sugar glass acts as a coating that 
provides the barrier to prevent molecules from aggregating [112]. The sugar glass 
matrix also reduces the lipid diffusion and molecular mobility (vitrification), thereby 
preventing degradation [113]. During the drying process, the sugars replace water 
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molecules for the hydrogen bond interactions with the active ingredients to preserve 
their structural integrity [114]. 
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2.5  Immunization with Influenza Vaccine 
 
2.5.1  Methods of Immunization 
 
Injection using hypodermic needles is still the primary method of vaccination of 
inactivated virus vaccines or split vaccines. But this method has some issues including 
pain, potential disease transmission if misused, needle-stick injury and disposal of 
biohazardous sharp waste. To address these issues, other delivery methods such as 
tape stripping, microneedles, thermal ablation, electroporation, and jet injection have 
been used to deliver vaccines [35]. The scope of this project only covered cutaneous 
immunization using microneedles. 
Microneedle’s ability to target immune cells in the epidermis makes it an 
excellent candidate for cutaneous vaccination. Modified vaccinia virus (a virus 
particle representative of some vaccines) has been shown to be uniformly coated on 
stainless steel microneedles [15]. Ovalbumin, a well-characterized antigen, has been 
coated with different doses on the Macroflux solid microneedle array for 
immunization studies in hairless guinea pigs. These immunization studies have shown 
that the induced immunization by microneedle arrays was comparable with 
intradermal vaccine delivery by hypodermic needles. At low doses the microneedle 
immunization was superior to IM delivery [115]. Influenza vaccination in rats has 
been carried out using a 34 Ga single hollow microneedle with a total exposed length 
of 1 mm. Dose sparing was achieved in some cases but the extent of dose sparing 
varied depending on the vaccine employed and the strain of influenza virus [116]. 
Recently, immunization of mice using solid microneedles coated with inactivated 
influenza virus has shown to generate an equivalent immune response compared to 
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intramuscular injection using hypodermic needles [117, 118]. However, more in vivo 
studies still need to be carried out to determine whether or not “microneedle 
vaccination” is superior to intramuscular vaccination using hypodermic needles. 
 
2.5.2  Vaccination in Developing Countries 
 
In 1974, the World health Organization (WHO) initiated the Expanded Program 
on Immunization (EPI) that aimed to immunize the world’s children against six 
diseases (diphtheria, tetanus, whooping cough, poliomyelitis, measles, and 
tuberculosis). The initiative was particularly challenging in the developing world at 
that time because less than 5% of the children were fully immunized and health 
infrastructure was missing [119]. In 1991, WHO and UNICEF announced that 80% of 
the world’s children were immunized with the EPI vaccines. While some regions, 
particularly in Africa, remained below the average of global immunization, the efforts 
of immunization programs have been shown effective, especially in Latin American 
where polio has been eliminated [119, 120]. According to the 1993 World 
Development Report compiled by the World Bank and WHO, communicable and 
perinatal diseases caused 60% of the disease burden of children under 14 and 80% of 
deaths of children under 5 in developing countries [121]. Although many of those 
diseases could be prevented by vaccines, the vaccines were not readily available in 
developing countries. Therefore, it is clear that developing countries are in need of 
vaccination for infectious disease prevention. However, the lack of trained personnel, 
facilities and capital impedes access to appropriate medical care. Three major 
problems associated with mass vaccination in the developing world are identified: 
vaccination cost, unsafe use of hypodermic needles, and vaccine storage. 
High vaccination cost is one of the primary reasons for shortage of vaccine 
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supply to the developing world. The cost is a comprehensive sum of vaccine 
manufacturing cost, delivery tool cost, transport and storage expenses, and trained 
personnel wages. A breakdown of immunization costs shows that out of the total cost 
of US $15 every full immunization against the six mentioned diseases, more than $14 
are spent on infrastructure including personnel and only less than $1 for the vaccines 
[119]. Based on the cost breakdown, elimination of infrastructure and personnel cost 
would drastically reduce the cost burden of vaccination. 
To avoid any additional cost, unsafe practices such as needle sharing or reuse in 
the developing world are common. It is estimated that 8-12 billion injections are given 
in health care settings globally each year [122, 123]. Unsafe practices account for 
more than 50% of the injections in developing countries [7]. Consequently, disease 
transmission such as hepatitis B and C, human immunodeficiency virus and other 
blood-borne pathogens has given rise to another health care issue.   
Another vaccination issue comes from transport and storage. From 
manufacturing to actual vaccine administration, the process is not a simple shipment 
of goods. Most vaccines require a storage temperature ranging from 2°C~8°C [124].  
Exposure to heat will reduce the vaccine shelf life [125]. Freezing will also cause 
irreversible damage to the vaccines that cannot be frozen [126, 127]. Cold chain, 
defined as a process carried out at a certain temperature range, is adopted for vaccine 
storage and transport. This process requires cold rooms and refrigerators for proper 
storage. Additional monitors and freeze indicators are often included in shipments.   
As a result, cold chain is an expensive process that shows no guarantee to the vaccine 
quality due to the vulnerability of liquid formulated vaccine to external temperature 
variation. 
To lower the cost of vaccination, to eliminate biohazardous sharp waste and 
needle reuse, and to store vaccine without specialized facilities or equipments, this 
 27
project aimed to improve and design new microneedle systems that address all of 
these problems for the benefit of health care in both industrialized and developing 
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3.1  Abstract 
 
Dissolving microneedle patches offer promise as a simple, minimally invasive 
method of drug and vaccine delivery to the skin that avoids the need for hypodermic 
needles. However, it can be difficult to control the amount and localization of drug 
within microneedles. In this study, we developed novel microneedle designs to 
improve control of drug encapsulation and delivery using dissolving polymer 
microneedles by (i) localizing drug in the microneedle tip, (ii) increasing the amount 
of drug loaded in microneedles while minimizing wastage, and (iii) inserting 
microneedles more fully into the skin. Drug localization in the microneedle tip was 
achieved by either casting a highly concentrated viscous polymer solution as the 
needle matrix or incorporating an air bubble at the base of the microneedle to prevent 
drug diffusion into the patch backing. As another approach, a pedestal was introduced 
to elevate each microneedle and thereby increase its drug loading capacity. The 
pedestal also enabled more complete microneedle penetration into the skin to ensure a 
greater percentage of the drug encapsulated in the microneedle was delivered into the 
skin. Altogether, these novel microneedle designs provide a new set of tools to 
fabricate dissolving polymer microneedles with improved control over drug 
encapsulation, loading and delivery. 
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3.2  Introduction 
 
Transdermal delivery as an alternative route to parenteral administration has 
gained increasing attention. A number of different transdermal patches delivering 
molecules less than approximately 500 Da and high lipophilicity such as nicotine, 
fentanyl and estrogen have been introduced commercially with significant clinical 
impact [3]. However, delivering biologics in the form of proteins or whole 
micro-organisms across intact skin is extremely difficult due to the presence of 
stratum corneum, i.e., the outer most layer of the skin. To overcome this skin barrier, 
microneedles offer a minimally invasive method that disrupts the stratum corneum in 
a relatively painless way [8, 128, 129]. Skin offers an excellent site for drug and 
vaccine delivery partly because delivering molecules via the skin bypasses intestinal 
and hepatic first-pass metabolisms. Moreover, the abundant presence of dendritic cells 
and Langerhans cells also makes skin an attractive site for vaccine delivery. 
Numerous studies have shown that the delivery of vaccines to the skin using 
intradermal injection or other methods that overcome the stratum corneum barrier 
effectively triggered immune response in animal models [130, 131]. 
Ideally, a skin delivery system should (i) deliver a broad range of therapeutics 
including small molecule drugs, macromolecules and biologics, (ii) have a controlled 
dose with high bioavailability, (iii) be safe, (iv) be simple to use, and (v) be 
inexpensive. Traditional non-invasive transdermal patch systems are simple to use and 
inexpensive, but the choice of therapeutics is limited to small molecules due to the 
presence of stratum corneum. In some cases, chemical enhancers have been used to 
facilitate the transport of molecules across the skin, but skin irritation can be a 
limitation [42, 132]. Other approaches have included supramolecular structures, such 
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as liposomes and emulsions, as well as physical approaches, such as iontophoresis, 
ultrasound, and thermal ablation [9, 133]. However, each method has shortcomings 
and has made only limited clinical impact to date.    
Recently, microneedles have shown the capability of delivering a variety of 
molecules into the skin, including drugs and vaccines [10, 14-16, 21, 75, 134-136]. 
Microneedles are micron-scale needles that are produced by adapting the tools of the 
microelectronics industry. Microneedles pierce across the stratum corneum and into 
the epidermis and/or superficial dermis to administer compounds into the skin for 
local or systemic administration. Microneedles can be assembled into patches, which 
offers simplicity of use and low cost similar to conventional transdermal patches. 
Studies have shown that coated microneedles can carry a controlled dose by coating 
the drug only onto a defined region on the needle substrate surface [15, 16, 117]. The 
coated drug is released from the microneedle upon insertion into the skin. A drawback 
of this approach, however, is that such microneedles leave behind sharp, biohazardous 
waste after use, which may present safety concerns and special disposal needs.  
Dissolving polymer needles have been developed by making microneedles out of 
water-soluble polymer that encapsulates drug within the needle matrix and fully 
dissolves upon insertion into the skin, thereby eliminating sharp biohazardous waste 
[20, 21, 23, 137, 138]. Thus, dissolving microneedles appear to be an attractive drug 
delivery system, because they are designed to deliver a wide range of therapeutics, are 
easy to use, are inexpensive, and leave no sharp waste after use. However, it can be 
difficult to control the dose encapsulated and delivered from polymer microneedles 
due in part to drug diffusion within the water-soluble microneedle matrix during 
fabrication.  
This study seeks to improve upon dissolving microneedle design by better 
controlling drug encapsulation and delivery. More specifically, we seek to overcome 
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the difficulties of controlling, loading and delivering a specified drug dose with 
dissolving microneedles using novel approaches that (i) localize drug only in the 
microneedle tip, (ii) increase the amount of drug loaded in microneedles while 
minimizing wastage, and (iii) insert microneedles more fully into the skin. To localize 
drug only in the microneedle tip, we prevented drug diffusion out of microneedles 
during fabrication by either using a highly concentrated polymer solution to increase 
viscosity or introducing an air bubble at the base of the needle that constrained the 
drug from diffusing into the backing. To increase the amount of drug loaded in 
microneedles while minimizing wastage, we added a pedestal at the base of the 
microneedle to provide extra volume to each microneedle, thereby increasing their 
overall drug loading capacity. Finally, to insert microneedles more fully into the skin, 
we again used the pedestal design to provide higher aspect-ratio microneedles capable 
of inserting more fully into the skin, but with sufficient mechanical strength to avoid 
failure during insertion.  
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3.3  Materials and Methods 
 
3.3.1  Fabrication of Microneedles 
 
3.3.1.1  Microneedle Molds 
 
Pyramid microneedle mold. A mold of a 10 x 10 array of 300 x 300 x 600 µm 
(W x L x H) pyramidal microneedles was fabricated using photolithography and 
molding techniques described previously [139, 140]. Briefly, a pyramidal microneedle 
mold was created by exposing SU-8 photoresist (SU-8 2025, Microchem, Newton, 
MA) to ultraviolet light. A microneedle master structure made out of 
polydimethylsiloxane (PDMS) (Sylgard 184, Dow Corning, Midland, MI) was 
molded off the SU-8 mold and coated with gold. Next, a PDMS mold replicate was 
created from the gold-coated master structure. Then, polylactic acid (PLA) (L-PLA, 
1.0 dL/g; Birmingham Polymer) was melted at 195°C under vacuum to fill the mold 
replicate and make a PLA master structure replicate. Finally, a PDMS mold replicate 
was made from the PLA master structure replicate.  
 Pedestal microneedle mold. A pedestal microneedle mold was made by aligning 
a PDMS microneedle mold containing a 10 x 10 array of 300 x 300 x 600 µm (W x L 
x H) pyramidal cavities with two laser-cut stainless steel sheets each containing a 10 x 
10 array of 340 x 340 x 150 µm (W x L x H) non-tapered through-holes. The pattern 
of the non-tapered through-holes was first drafted in AutoCAD software (Autodesk, 
Cupertino, CA) and then cut into 150 µm stainless steel sheets (McMaster-Carr, 
Atlanta, GA) using an infrared laser (Resonetics Maestro, Nashua, NH) at a cutting 
velocity of 1 mm/s with 10% attenuation of laser energy. The laser-cut metal sheets 
were electropolished (E399 electropolisher, ESMA, South Holland, IL) for 10 min at 
2 A in a 74°C mixture of glycerin, 85% ortho-phosphoric acid and water (6:3:1 by 
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volume) (Fisher Scientific, Fair Lawn, JN). The electropolished metal sheets were 
washed briefly with 30% nitric acid solution at room temperature and blow-dried with 
nitrogen gas. Individual metal arrays patterned with 10 x 10 through-holes were 
detached from their mother electropolished metal sheet. Each metal array was then 
coated with a thin PDMS film by dipping into a pre-cured PDMS and spinning at 672 
x g for 1 min (GS-15R, Beckman, Fullerton, CA). Two 150 µm-thick metal arrays 
coated with PDMS were aligned and stacked on top of the PDMS mold. An integrated 
metal-PDMS composite mold was formed as the PDMS coating adhered the metal 
sheets and PDMS mold together upon curing at 150°C for 10 min. 
  Extended pyramidal microneedle mold. Extended pyramidal microneedle master 
structure was made by trimming off the projected portion of the 340 x 340 x 300 µm 
pedestal into a tapered structure with an extended microneedle base of 300 x 300 x 
300 µm (W x L x H) using a razor blade (VWR). Polyvinyl alcohol (PVA) (MW 2000, 
ACROS Organics) was dissolved in DI water (50 wt %) and was used to smoothen 
the rough surfaces of the tapered needle structure. The viscous polymer solution was 
applied and then coated onto the tapered microneedle structure by centrifuge at 3200 
x g at 25°C for 1 hr. After the polymer film was centrifuge dried, extended pyramidal 
microneedle mold was made by curing the PDMS on top of the extended microneedle 
structure coated with a PVA film at 37°C overnight. 
  
3.3.1.2  Preparation of Microneedle Matrix Material 
 
The microneedle matrix material was a polymer blend consisting of polyvinyl 
alcohol (PVA, MW 2000) (ACROS Organics) and polyvinylpyrrolidone (PVP) (BASF, 
K17, Aktiengesellschaft, Ludwigshafen, Germany) (ratio 3:1). To make a 50 wt % 
polymer solution, 3 g PVA was dispersed in 4 ml DI water and heated at 60°C for 3 h. 
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Then, 1 g PVP was added to the PVA solution and mixed thoroughly using a spatula. 
The polymer blend was incubated at 37°C in a sealed glass bottle overnight. Similarly, 
30 and 40 wt% polymer solutions were also prepared. Unless indicated, a 50 wt% 
polymer solution was used to fabricate the microneedles.  
 
3.3.1.3  Drug Loading into the Mold 
 
Sulforhodamine B (Molecular Probes, Eugene, OR) was used as the model drug 
and was dissolved in DI water to prepare stock solutions at concentrations of 1 mg/ml 
and 10 mg/ml. Two methods of drug loading were used for different studies. The first 
method was a two-step process that first loaded and dried the drug solution in the 
mold cavities and then cast the polymer solution into the mold. This method created a 
drug gradient in which the tip of the microneedle had the highest concentration. 
Sulforhodamine stock solution was pipetted onto the top of a PDMS mold to cover the 
cavities and then was vacuumed at room temperature to – 91 kPa for 3 min. After 
vacuuming, residual sulforhodamine on the mold surface was pipetted off and 
recycled for reuse. The PDMS mold filled with sulforhodamine was then dried under 
centrifugation at 3200 x g at room temperature for several minutes. Dried 
sulforhodamine adherent to the mold surface was removed by Scotch tape (3M, St. 
Paul, MN). The second method involved the direct casting and drying of a pre-mixed 
drug and polymer solution, as described below. Using this method, the drug was 






3.3.1.4  Polymer Casting into the Mold 
 
Approximately 150 µl PVA/PVP blend solution was applied to cover the entire 
array of microneedle cavities in the mold. The mold covered with polymer solution 
was vacuumed at room temperature to – 91K Pa for 5 min. To fabricate solid 
microneedles, the residual polymer on the mold surface was left to dry at room 
temperature. To make bubble microneedles, the residual polymer was spun off by 
centrifuging at 3200 x g at room temperature for 5 min and then dried at room 
temperature. 
 
3.3.1.5  Backing Assembly 
 
The backing layer was assembled differently for solid and bubble microneedles. 
To assemble the backing for bubble microneedles, a small piece of office paper 
(approx. 1 cm x 1cm) was coated with a thin film of a highly concentrated PVA/PVP 
solution and placed on top of the mold after polymer casting and drying. The 
assembled mold was then dried at room temperature over night. For solid needles, no 
additional backing assembly was done, because the residual polymer left on the mold 
surface was used as the backing after drying. In both cases, after the microneedles and 
backing were both dried, the resulting microneedle array was detached from the mold 
using double-sided adhesive tape (444 Double-Sided Polyester Film Tape, 3M,). The 
microneedle array was then attached to a SEM mount (Structure Probe, West Chester, 




3.3.2  In Vitro Microneedle Insertion Assessment 
 
3.3.2.1  Microneedle Insertion into Skin 
 
Porcine cadaver skin (Pel-Freez, Rogers, AR) was shaved using a razor (Dynarex, 
Orangeburg, NY). The skin’s subcutaneous fat was removed by a scalpel (Feather, 
Osaka, Japan). The processed skin was laid flat on a cutting board at room 
temperature. The surface of the skin was dried with a paper towel. Microneedles were 
manually inserted into the skin while positioning two fingers on either side of the 
intended insertion site to keep it under mild tension. These microneedles were 
inserted by pushing against the skin with a distance of approximately 1 cm from the 
skin surface. Pyramidal, extended pyramidal and pedestal microneedles containing 
sulforhodamine were each manually inserted into the skin for 30 s, 2 min and 10 min. 
Each subset of microneedles for each insertion time had at least 3 replicates. The 
microneedles were microscopically imaged before and after insertion (Olympus 
SZX16, Pittsburgh, PA). 
 
3.3.2.2  Imaging and Histology 
 
The microneedle insertion sites were excised from the bulk skin with a scalpel. 
The isolated skin pieces were placed in cryostat molds embedded in optimum cutting 
temperature (OCT) media (Tissue-Tek, Torrance, CA). The skin was fixed in OCT by 
freezing the sample on dry ice. Frozen skin samples were sliced into 12-µm thick 
sections (Cryo-star HM 560MV, Microm, Waldorf, Germany). The skin sections were 
stained with hematoxylin and eosin using an automated staining machine (Leica 
Autostainer XL, Nussloch, Germany). After staining, the sections were covered with 
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glass slides sealed with cytoseal 60 (low viscosity, Richard-Allan Scientific, 
Kalamazoo, MI). The sections were dried overnight before taking images under the 
microscope (Nikon E600, Tokyo, Japan).    
 
3.3.3  Bioavailability 
 
3.3.3.1  Spectrofluorometer 
 
The amount of drug delivered into the skin was determined based on a mass 
balance of three parameters: the total amount of drug encapsulated in microneedles 
before insertion into skin, the amount of drug remaining in needles after insertion and 
removal from skin, and the residual drug left on the skin surface. After the needles 
were removed from the insertion site, adhesive tape (3M, St. Paul, MN) was used to 
strip off the residual dye left on the skin surface. The microneedles and skin-stripped 
tapes were then soaked in DI water in separate containers for 30 min at room 
temperature. The samples were transferred into cuvettes and measured by 
spectrofluorometry (Photon Technology International, Lawrenceville, NJ). The 
excitation wavelength of sulforhodamine was set at 565 nm. Area under the curve 
from 580 nm to 620 nm was calculated using Felix software (Photon Technology 
International). This reading was fitted into the sulforhodamine standard curve to 
obtain the actual amount of sulforhodamine by mass. The amount of sulforhodamine 
delivered into the skin was determined by subtracting the amount of sulforhodamine 
left in the needles and on the skin surface from the amount originally encapsulated in 
the microneedles. 
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3.4  Results 
 
3.4.1  Microneedle Fabrication 
 
In this study, we introduced new fabrication processes to better control drug 
encapsulation within dissolving microneedles. Microneedles with pyramidal geometry 
were fabricated by a series of molding and casting techniques. In this process, drug 
was loaded selectively into the microneedles (i.e., and not in the backing). We did not 
want to spread the drug solution to cover the entire microneedle mold and then dry it 
because this method could result in non-uniform drug loading or large amounts of 
drug wastage in the backing. Instead, we loaded the drug into the microneedle cavities 
of the mold (Fig. 3.1A) and then recycled the residual drug solution on the mold 
surface using pipettes to avoid wastage (Fig. 3.1B). To keep the drug localized in the 
microneedle cavities of the mold, we evaporated the drug solution to leave a solid 
drug film in the tips of the mold cavities prior to casting the polymer solution (Fig. 
3.1C and 3.1D).  
We next formed the microneedle base and backing using different methods to 
produce microneedles of two different designs: solid microneedles and bubble 
microneedles. Solid needles were made by casting sufficient polymer solution to form 
the microneedle base and backing after drying (Fig. 3.1E1). The dried microneedles 
were then peeled off from the mold (Fig. 3.1F1). To make bubble needles, the 
polymer solution outside the mold cavities was spun off the mold surface. Upon 
drying, the polymer solution in the mold cavities solidified with a meniscus-like shape 
in each microneedle cavity (Fig. 3.1E2). Upon applying a second layer of polymer 
solution to the mold surface, surface tension effects prevented it from filling the 
empty space in the mold cavities defined by the polymer meniscus. After drying, this 
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Fig. 3.1. Schematic of solid and bubble needle fabrication process. (A) A PDMS 
microneedle mold [140] was filled with drug solution under vacuum; (B) Residual 
drug solution was removed from the surface by a pipette and later reused; (C) Drug 
solution in the mold cavities was dried under centrifugation; (D) Drug-free polymer 
solution was cast onto the mold and filled under vacuum; (E1) The polymer solution 
was either air-dried or dried under centrifugation at low speeds; (F1) Dried solid 
needles were peeled off the mold by an adhesive backing; (E2) The polymer solution 
was either physically scraped off the mold surface and then air-dried or dried under 
centrifugation at high speeds; (F2) A backing coated with a thin film of concentrated 
polymer solution was placed on top of the mold and then air dried. After drying, the 
bubble needles were peeled off. 
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Using this fabrication approach, the maximum amount of drug loaded into each 
microneedle is the produce to the microneedle cavity volume times the drug solubility 
in its carrier solvent. One approach to increase drug loading per microneedle would be 
to use a solvent that increases drug solubility, although choice of solvents is also 
limited by safety considerations. Another possibility would be to overcome the 
solubility limit by using particulate systems in which drug particles are suspended in 
the carrier solvent. However, particle size must be much smaller than microneedle 
size and such systems can lead to non-uniform needle-to-needle loading. As another 
alternative, we increased loading capacity of microneedles by effectively increasing 
microneedle mold cavity volume by adding a pedestal at the base of each mold cavity. 
To accomplish this, the pyramidal PDMS mold was reverse-molded from a master 
microneedle needle structure (Fig. 3.2A). We then aligned PDMS-coated laser-cut 
stainless steel sheets with the PDMS mold (Fig. 3.2B and 3.2C). In this way, each 
pyramidal cavity in the mold was positioned immediately below a hole in the stacked 
metal sheets above. This created enlarged microneedle mold cavities consisting of a 
non-tapered pedestal at the base of the pyramidal needle tip. Pedestal microneedles 



















Fig. 3.2. Schematic of pedestal microneedle mold fabrication. (A) A PDMS mold was 
created from a master microneedle structure. (B) An infrared laser-cut metal sheet was 
coated with PDMS; (C) A composite mold was formed as the coated metal sheet(s) 
were placed on top of the PDMS mold and cured under heat; (D) Molten polymer was 
cast onto the composite mold by vacuum; (E) After cooling, microneedles with 
pedestal structure were peeled off the composite mold; (F) The pedestal microneedles 
were then used as the master structure for making pedestal PDMS mold replicates 
(see Fig. 3.1). 
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3.4.2  Drug Localization and Delivery Efficiency 
 
One of our goals was to develop methods to load and localize drug in the tips of 
the microneedles. Using the solid microneedles, we found that polymer concentration 
in the casting solution had an important effect. As shown in Fig. 3.3A, using a low 
concentration casting solution (30 wt %) led to distribution of the model drug, 
sulforhodamine, throughout the needle and into the backing. We believe that the low 
viscosity of the low concentration casting solution allowed sulforhodamine to diffuse 
out of the microneedle mold cavity through the microneedle matrix during drying in 
the microneedle mold. Consistent with this hypothesis, increasing viscosity by 
increasing the polymer concentration (40 wt %) better kept the sulforhodamine within 
the needle (Fig. 3.3B). Casting at a still higher polymer concentration (50 wt %) 
localized the sulforhodamine even more to the microneedle tip (Fig. 3.3C).  
Because microneedle formulations are subject to many constraints such that 
sufficiently increasing casting solution viscosity may be problematic, we developed 
another approach to keeping drug in the microneedle tip by introducing an air bubble 
at the base of the microneedle. Using this approach, sulforhodamine was contained 
within the microneedle independent of polymer concentration (Fig. 3.3D, 3.3E and 
3.3F). We believe this was because the bubble formed a physical barrier that 
prevented diffusion out of the microneedle. As an aside, the bubble also decreased the 
mechanical strength of the microneedles, which could be a limitation in some 
situations. However, under the conditions used in this study we found that bubble 
microneedles inserted reliably into skin and did not ever break.  
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Fig. 3.3. Solid and bubble microneedles loaded with model drug localized to the tips 
imaged by bright field microscopy. Top row: Solid needles loaded with 1 mg/ml 
sulforhodamine B encapsulated in (A) 30 wt %; (B) 40 wt %; (C) 50 wt % PVA/PVP 
blends. Bottom row: Bubble needle counterparts loaded with 1 mg/ml sulforhodamine 
B encapsulated in (D) 30 wt %; (E) 40 wt %; (F) 50 wt % PVA/PVP blends. The 
arrows indicate the location of air bubbles. Bar = 300 µm.   
 
We were motivated to keep sulforhodamine localized in the tips of the 
microneedles because we expected that to enable more efficient drug delivery into the 
skin (i.e., leaving less drug remaining in the microneedle device). To test this 
expectation, we inserted solid and bubble microneedles made using different polymer 
concentrations into porcine cadaver skin and monitored drug release over time. As 
shown in Fig. 3.4, delivery efficiency was highly correlated with drug localization. 
Microneedles with drug localized in the microneedle tip (i.e., Solid 50%, Bubble 50% 
and Bubble 40%) showed an initial burst release of sulforhodamine within the first 30 
s resulting in approximately 80% drug release within 10 min. Microneedles with 
sulforhodamine distributed throughout the needle matrix but not in the backing (i.e., 
Solid 40% and Bubble 30%) had a smaller burst release, but then delivery efficiency 
increased over time to approximately 70% drug release, probably due to continued 
microneedle matrix dissolution. Finally, microneedles with sulforhodamine 
distributed into the backing demonstrated low delivery efficiency corresponding to 
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only about 20% drug release. The delivery did not significantly increase with time, 
suggested that 10 min was insufficient time for the sulforhodamine in the backing to 






























Fig. 3.4. Percentage delivery of sulforhodamine B over the time during microneedle 
insertion into porcine cadaver skin. Solid lines are for solid microneedles and dashed 
lines are for bubble microneedles made using different polymer solution 
concentrations. Data points represent averages of n = 3 replications, with standard 
deviation bars shown. 
 
3.4.3  Drug Loading Capacity and Variability 
 
Our second goal was to increase drug loading in the microneedles without wastage 
in the backing. To achieve a higher loading in the microneedles, we made larger 
microneedle mold cavities, which enabled more drug solution to be cast into each 
cavity and resulted in larger microneedles. We did not change the tip geometry, 
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because it is critical to microneedle insertion into the skin. Instead we elongated the 
base portion of the needle either in a tapered fashion, which resulted in “extended 
pyramidal” microneedles or with a non-tapered structure, which generated “pedestal” 
microneedles. The original pyramidal needle has a volume of 18 nl. Elongating the 
base in the extended pyramidal needle increased the volume to 45 nl, which is two 
and a half times larger than the pyramidal needle. The pedestal microneedle volume 
was increased to 53 nl, which is almost three times larger than the pyramidal needle. 
As an example, casting with a solution containing 10 mg/ml of drug results in 0.53 µg 
of drug encapsulated per needle (i.e., 53 µg in 100 needles or 530 µg in 1000 needles). 
These doses are sufficient for many vaccines and protein therapeutics [141, 142]. 
We made measurements of drug loading dose to assess reproducibility and 
wastage. As shown in Table 3.1, the amount of sulforhodamine encapsulated within 
microneedles was determined at two different drug concentrations in the casting 
solution and using the three different microneedle designs. We found that the amount 
encapsulated within the microneedles was close to that predicted as the product of 
microneedle mold cavity volume times drug concentration, although there was some 
deviation especially when lower drug concentration was used. The device-to-device 
variability ranged from 0.1 µg to 0.92 µg per 100 microneedles on an absolute basis, 

















 Extended Pyramidal  Pedestal 
Miconeedle mold cavity 
volume 
(per 100 microneedles) 
1.80 µl  4.50 µl  5.30 µl 
 
Drug concentration in the 
coating solution 
1 mg/ml 10 mg/ml  1 mg/ml 10 mg/ml  1 mg/ml 10 mg/ml 
 
Drug loaded after 
encapsulation  
(per 100 microneedles) 
1.33 ± 0.1 
µg 
18.10 ± 0.74 
µg 
 
4.16 ± 0.45 
µg 
40.55 ± 0.62 
µg 
 
6.37 ± 0.44 
µg 
54.30 ± 0.92 
µg 
         
Drug wastage during 
fabrication (per 100 
microneedles) 
0.11 ± 0.09 
µg 
1.13 ± 0.29 
µg 
 
0.19 ± 0.03 
µg 
1.36 ± 0.63 
µg 
 
0.08 ± 0.1 
µg 
1.28 ± 0.3 
µg 
 
Drug wastage, as assessed by the amount of drug left on the mold surface (i.e., not 
inside a mold cavity), scaled with drug concentration and was relatively independent 
of mold geometry. Wastage ranged from 0.08 µg to 0.19 µg when casting with 1 
mg/ml sulforhodamine and from 1.13 µg to 1.36 µg when casting at 10 mg/ml. This 
corresponds to a residual volume on the mold surface on the order of 100 nl per 
100-needle array. Because the absolute wastage amount was relatively independent of 
mold geometry, drug wastage was just 4 – 3 % for the extended pyramid needles and 
1 – 2 % for the pedestal needles. We expect that these values could be further reduced 






3.4.4  Microneedle Insertion Depth  
 
Our third goal was to achieve a more complete insertion of microneedles into the 
skin. We hypothesized that by inserting microneedles more fully would result in 
higher drug bioavailability in the skin. The extended pyramid and pedestal 
microneedles achieved greater drug loading by elongating the needle base, which 
makes the needles longer. Because skin deflection during microneedle insertion can 
result in a significant fraction of the needle remaining outside the skin [23, 143], the 
original pyramidal microneedles are not expected to fully insert. However, mounting 
them on a pedestal or on an elongated based should facilitate full insertion of the 
microneedle tip, in which the drug is encapsulated. Clearly, there is a limit to how far 
this strategy can be carried forward. Still longer microneedles should encapsulate 
more drug and insert more fully into the skin. However, if the microneedles become 
too big, then they will hurt, which should reduce patient acceptance.  
To study this issue, pyramidal microneedles, extended pyramidal microneedles 
and pedestal microneedles were fabricated as shown in Fig. 3.5A, 3.5B and 3.5C. The 
pyramidal microneedles were 600 µm long and the extended pyramidal and pedestal 
needles were 900 µm long. We determined the depth of microneedle insertion and its 
impact on the amount of drug delivered to the skin in three ways. First, we examined 
the histological cross sections of skin at the insertion sites. As shown in the 
representative images in Figs. 3.5A1, 3.5B1 and 3.5C1, pyramidal microneedles 
inserted to a depth of approximately 150 µm, whereas both the extended pyramidal 
and pedestal needles inserted to a depth of approximately 250 µm into the porcine 
cadaver skin, which was similar to 250 µm length of the drug-loaded tip portion of the 
needles. Although the pedestal needles had a bulkier base than the extended pyramidal 
needles, the pedestal did not appear to hamper insertion, perhaps because the base 
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portion of the microneedle was primarily used to overcome skin deflection and did 




Fig. 3.5. Skin insertion depth of three different microneedle structures imaged by 
bright field microscopy. (A) Pyramidal microneedles (base width x base depth x 
needle height: 300 x 300 x 600 µm); (B) Extended pyramidal microneedles (300 x 
300 x 900 µm) and (C) Pedestal microneedles (340 x 340 x 900 µm). Corresponding 
H&E-stained histology cross sectional images of insertion sites in porcine cadaver 
skin: (A1) Pyramidal microneedles; (B1) Extended pyramidal microneedles and (C1) 
Pedestal microneedles. The arrows indicate the depth of the microneedle insertion 
track. Bar = 200 µm. 
 
As a second assessment, we determined how the insertion depth affected the 
dissolution of the microneedles. As determined by microscopic examination of 
needles after 10 min insertion, we found that pyramidal needles lost approximately 
50% of their original length from 600 µm to 300 µm (Fig. 3.6A and 3.6A1). Because 
of the tapered geometry, this corresponds to a 12% loss in microneedle volume. In 
contrast, both the extended pyramidal needles and pedestal needles lost almost 80% of 
their lengths, reducing from 900 µm to 450 µm (Fig. 3.6B, 3.6B1, and 3.6C, 3.6C1). 
This corresponds to complete dissolution of the upper 450 µm containing the 






Fig. 3.6. Microneedle dissolution after insertion into porcine cadaver skin imaged by 
bright field microscopy. Left column shows microneedles uniformly loaded with 1 
mg/ml sulforhodamine before insertion into skin. (A) Pyramidal microneedle; (B) 
Extended pyramidal microneedle; (C) Pedestal microneedle. Right column shows 
corresponding microneedles after a 2 min insertion into skin. The arrows indicate the 
base of the primary 600 µm microneedle structure at its interface with the extended 
pyramidal portion or pedestal portion. Bar = 300 µm.  
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Third, we further determined the amount of delivery by quantifying the 
efficiency of microneedle insertion and dissolution in the skin based on the amount of 
encapsulated drug released during the insertion. To facilitate this analysis, we 
encapsulated the model drug, sulforhodamine, uniformly throughout the microneedle 
rather than localizing it in the tips. A mass balance on the amount of sulforhodamine 
initially encapsulated and that remaining after insertion showed that the pyramidal 
needles lost almost 10% of their original volume, where as both the extended 
pyramidal and pedestal needles lost almost 50% of their microneedle matrix (Fig. 3.7). 
Altogether, these three methods of assessment reach the common conclusion that the 
elongated microneedle geometries enable a deeper insertion and more efficient 









Fig. 3.7. Microneedle dissolution after insertion into porcine cadaver skin as 
determined by a quantitative mass balance. Loss of micronneedle volume was 
determined based on the amount of sulforhodamine encapsulated in microneedles 
before and after insertion in skin. Data points represent averages of n = 3 replications, 
with standard deviation bars shown.  
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3.5  Discussion 
 
Dissolving polymer microneedles offer a simple, safe, and minimally invasive 
delivery method to the skin. Yet, due to the need for water-based casting of the 
polymer when molding the needles, drug encapsulation, loading and delivery can be 
difficult to control. We addressed these issues by (1) localizing drug only in the 
microneedle tip, (2) increasing the amount of drug loaded in microneedles while 
minimizing wastage, and (3) inserting microneedles more fully into the skin. 
Localizing drug only in the microneedle tip required control of drug deposition 
in the tip during casting as well as minimizing drug diffusion out of the tip during 
drying. When the drug and polymer matrix material were premixed and cast onto the 
microneedle mold together, the volume of this mixture would take up too much space 
in the microneedle mold upon drying and thereby make localization in the 
microneedle tip difficult. In this study, we showed that drug localization in the tip can 
be better achieved by first casting a solution containing drug with little or no added 
excipients and then drying the drug into the tip of the microneedle mold under 
centrifugal force. As a second step, this was followed by casting and drying the 
polymer solution to form the rest of the microneedle matrix.  
During this second step, diffusion of drug out of the tip can take place as the 
dried drug makes contact with, dissolves in and diffuses through the aqueous polymer 
solution. As shown in Fig. 3.3, drug diffusion during this step is affected by polymer 
concentration, such that a higher concentration solution inhibited diffusion and helped 
maintain drug localization in the tip. However, use of highly concentrated polymer 
solutions can be constrained by their physical characteristics including high viscosity, 
poor solubility or gelation, which can make processing during fabrication difficult.  
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As an alternative to blocking diffusion through the use of concentrated polymer 
solutions, we introduced a new technique in which dilute polymer solution could be 
used and drug diffusion from the tip was blocked by incorporating a bubble at the 
base of each microneedle. In this approach, the excess polymer was spun off the mold 
surface and, after drying, a concave drug film was formed in the base of each 
microneedle mold cavity, as shown in Fig. 3.1E2. Instead of refilling the hollowed 
cavity, which could re-dissolve the drug, the hollow cavity was left unfilled and 
capped with a backing layer containing little moisture. The outcome of this technique 
was an entrapped air bubble that blocked drug diffusion. Comparing the bubble 
needles with their solid needle counterparts, the bubble needles had more defined 
drug localization even in microneedles made up of dilute polymer solutions. 
Moreover, microneedles with better drug localization showed greater delivery 
efficiency compared to the ones with less effective drug localization.    
In addition to localizing drug into the microneedle tip, we also sought to 
maximize the dose encapsulated in a microneedle while avoiding the wastage of drug. 
Any drug that dried on the mold surface was considered wasted because it could not 
be recycled or delivered into the skin easily. To minimize drug wastage, we only 
loaded drug solutions in the microneedle mold cavities, which resulted in the dose 
encapsulated per needle being constrained by the volume of the needle itself. To 
address this limitation, we modified the pyramidal needles by introducing two 
additional structures: extended pyramidal needles and pedestal needles. These new 
microneedle structures bulked up the original pyramidal needle volume from 0.018 µl 
to 0.045 and 0.053 µl respectively. The amount of drug wastage was independent of 
the microneedle structure. Rather, the wastage was determined by the amount of 
unrecycled drug left on the mold surface. As a result, encapsulating larger doses was 
preferred because the relative percent wastage of drug became less significant as we 
 54
increased the dose (Table 1).  
Skin deflection and elasticity is one of the main causes for incomplete insertion 
of microneedles. The degree of skin deflection depends on a variety of factors 
including microneedle tip sharpness, microneedle aspect ratio, needle-to-needle 
spacing, microneedle length and insertion speed. Because the matrix of dissolving 
polymer microneedles is weaker (i.e., has a smaller Young’s modulus) than, for 
example, metal microneedles, dissolving microneedle geometry must provide added 
mechanical strength, which usually results in a wide needle (i.e., smaller aspect ratio). 
This geometry makes dissolving microneedles more difficult to insert fully into the 
skin compared to, for example, the slender, high-aspect ratio metal needles used in 
other studies [15, 18, 115, 144]. 
As the needles are inserted into the skin, the insertion stops as the deflected skin 
surface hits the backing of the needle array, which prevents the needles from further 
piercing. To reduce the impact of this issue, we elevated the microneedles by adding a 
pedestal to the base of the microneedle. According to Fig. 3.5, we found that the 
additional 300 µm offered by the pedestal only resulted in an additional 100 µm 
insertion depth. This may be because the pedestal only partially overcame the skin 
deflection without the presence of physiological skin tension in our in vitro apparatus. 
In principle, needle length could be extended longer, but in practice, it would be 
difficult to remove dissolving microneedles longer than 1 mm from the PDMS mold 
and pain caused by such long needles may become a concern [145].  
Controlled dosing administered by dissolving microneedles plays a critical role 
in their eventual use in medicine. Some compounds such as biotherapeutics and 
vaccines are relatively expensive to produce. A controlled drug encapsulation process 
with minimal wastage reduces the overall cost of a microneedle patch, especially for 
costly drugs. In some cases, when a drug has a narrow therapeutic window, controlled 
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dosing becomes crucial to avoid over-or under-dosing. Another important aspect of 
this study is the more complete insertion of microneedles. People in different age 
groups and in different weight categories have different skin mechanical properties. 
The ability to insert microneedles more fully into the skin reduces the likelihood of 
delivery failure due to variable skin types. Overall, the new fabrication techniques 




3.6  Conclusions 
 
We have introduced new methods to fabricate dissolving microneedles for 
controlled drug encapsulation and delivery. These new microneedle designs and drug 
loading techniques enabled more drug to be loaded and localized into the microneedle 
tip with minimal drug wastage. By incorporating a pedestal at the base of the 
microneedle, microneedles could insert more fully. More complete insertion of the 
microneedles allowed a higher fraction of the encapsulated drug to be delivered into 
the skin. Overall, these technical advancements of controlled encapsulation and 
delivery provide an important step toward developing dissolving microneedles to 
serve as a reliable, versatile and safe delivery tool for administering a wide range of 
therapeutics. 
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4.1  Abstract 
 
To overcome the pain and risk of biohazardous sharp waste associated with 
hypodermic needles, we introduce a novel delivery tool called separable arrowhead 
microneedles. These needles are featured by capping micron-size sharp tips onto blunt 
shafts. Upon insertion into the skin, the tips containing drug or vaccine dissolve or are 
mechanically separated from the shafts on the scale of seconds. After administration, 
the needle shafts become dull and can not be reused. As a result, concerns for 
biohazardous sharp waste disposal and needle-stick injury are reduced. Thus, drug 
and vaccine delivery using arrowhead microneedles can be a quick, convenient, safe 
and potentially self-administered method.  
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4.2  Introduction 
 
Currently, biopharmaceuticals and vaccines are delivered almost exclusively by 
subcutaneous or intramuscular injection using hypodermic needles. While 
hypodermic needles have a long history of use in clinical practice, many issues such 
as patient incompliance due to needle phobia, sharing and reuse of needles, as well as 
disposal of sharp waste exist. Patient incompliance due to needle phobia is prevalent 
[4]; it presents impediments to clinical practice as the fear of injection reduces the 
willingness to be treated or vaccinated [5, 146]. Unsafe injection practices such as 
needle sharing and reuse accounted for more than 50% of the total injections in 
developing countries [7], leading to transmission of blood-born pathogens including 
hepatitis B, C and HIV. In addition to safety concerns of disposing hypodermic 
needles, handling and proper disposal of such biohazardous sharp waste can also be 
economic burdensome [147]. Summing all the costs from the societal perspective 
including device purchase and usage, medical costs and lost productivity, 
conventional disposable needle-and-syringe systems are one of the most expensive 
injection devices compared to other automated injection systems and jet-injectors 
[148].  
There has been a wave of effort to seek alternative methods other than using 
hypodermic needles to deliver drugs and vaccines through the skin. Non-invasive 
approaches using transdermal patches primarily deliver small molecules less than 
approximately 500 Da or highly lypohilic molecules passively through the skin [3]. To 
deliver macromolecules across the skin, stratum corneum, the outermost barrier of the 
skin, needs to be altered or removed. Tape stripping [59], dermabrasion [60, 61] and 
thermal ablation [3, 56] have shown to remove stratum corneum selectively without 
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damaging deeper tissues. However, administration using such methods requires a 
two-step process that involves stratum corneum removal and subsequent drug 
application.        
Microneedles are microscopic needles that create tiny channels in the skin upon 
insertion. Recently, molecules have been incorporated into microneedles forming an 
all-in-one delivery device which requires only a single application to deliver a full 
dose. For example, molecules were coated onto sharp, mechanically robust substrates 
for subsequent release in the skin [15-17]. These drug-coated microneedles minimize 
the risk of needle-stick injury due to their miniaturized size, but concerns for sharp 
waste disposal and needle reuse still remain. Molecules can also be encapsulated 
within dissolving microneedles made of water-soluble materials. When inserting 
dissolving microneedles into the skin, their water-soluble sharp tips dissolve and then 
release the encapsulated molecules within the skin [20-23]. While dissolving 
microneedles do not generate sharp waste, they have lower young’s modulus 
compared to, for example, coated metal needles. Weaker mechanical properties of 
dissolving microneedles pose some limitations: high-aspect ratio needles may risk 
mechanical failure during insertion while low-aspect ratio needles may result 
incomplete insertion of needles due to skin deflection [18, 23].  
Considering all the advantages and disadvantages of current cutaneous delivery 
tools including hypodermic needles and different microneedle designs, we introduce a 
novel type of microneedles called arrowhead microneedles. These needles are 
featured by capping sharp dissolvable or biodegradable tips onto mechanically robust 
dull shafts. This study covers step-by-step fabrication process of arrowhead 
microneedles. We also evaluated the insertion of arrowhead microneedles into cadaver 
skin and tested the safety of the device after use. 
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4.3  Materials and Methods 
 
4.3.1  Microneedle Fabrication 
 
4.3.1.1  Microneedle Mold 
 
A 10 x 10 array of polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, 
Midland, MI) pyramidal microneedle mold was fabricated by Choi et al using 
photolithography and molding techniques [140]. Each pyramidal microneedle cavity 
was 600 µm deep with a 300 µm x 300 µm square base. Polylactic acid (PLA) 
microneedle master structure was made by casting molten PLA (L-PLA, 1.0 dL/g; 
Birmingham Polymer, Pelham, AL) onto the PDMS mold by vacuum at – 91k Pa for 1 
h at 195°C. PDMS mold replicates were made by curing PDMS mixture on top of the 
PLA master structure at 37°C overnight. 
 
4.3.1.2.  Fabrication of Microneedle Shafts and Backing 
 
A 125 µm-thick stainless steel sheet (McMaster-Carr, Atlanta, GA) was cut using 
infrared laser (Resonetics Maestro, Nashua, NH) at a cutting velocity of 1 mm/s with 
one pass, 20% attenuation of laser energy, and air purge at a constant pressure of 140 
kPa based on AutoCAD (Autodesk, Cupertino, CA) drawings. Laser-patterned shafts 
on the metal sheet were bent 90° out-of-plane using a razor blade (VWR) while 
viewing under a microscope. The processed metal pieces with bent shafts were 
electropolished using electropolishing solution (E972, ESMA Inc., South Holland, IL) 
in E399 electropolisher (ESMA Inc.) for 15 min at 2 A at 45°C. The electropolished 
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metal pieces were briefly rinsed in 30% nitric acid solution, cleaned with DI water 
and blow-dried with nitrogen gas. 
    
4.3.1.3. Microneedle Matrix and Formulation Preparation 
 
Model drug sulforhodamine B (Molecular Probes, Eugene, OR) was dissolved in 
DI water at a concentration of 5 mg/ml. To encapsulate sulforhodamine B, a polymer 
blend consisting polyvinyl alcohol (PVA) (ACROS Organics, MW 2000) and 
polyvinylpyrrolidone (PVP) (BASF, K17, Aktiengesellschaft, Ludwigshafen, 
Germany) (ratio 1:1) was prepared. PVA was dispersed in DI water at 25°C and then 
heated to 90°C for 1 h. PVP was added and mixed homogeneously with the PVA 
solution. The polymer blend was incubated at 60°C for a few hours and cooled to 
room temperature before use. To encapsulate vaccine (inactivated influenza virus in 
PBS) (A/Puerto Rico/8/34, Emory Vaccine Center, Atlanta, GA), a blend of PVA and 
sucrose (Sigma-Aldrich, St Louis, MO) was used (ratio 1:1). Similarly, sucrose was 
mixed homogeneously with the PVA solution at 60°C and cooled to 25°C before use. 
 
4.3.1.4. Drug Loading and Polymer Blend Casting 
 
Sulforhodamine B or inactivated influenza virus was loaded into the PDMS mold 
by vacuuming to – 91k Pa for 3 min. The residual drug or vaccine on the mold surface 
was recycled by pipettes. The mold filled with drug or vaccine was centrifuged at 
3200 x g at room temperature for 3 min. The drug-free polymer blend was cast onto 
the mold by vacuuming to -91k Pa for 3 min, and centrifuged again at 3200 x g at 




4.3.1.5  Shaft Alignment and Drying 
 
Before the polymer blend cast on the mold became completely dried, 
electropolished shaft array was aligned manually to the mold cavities under a stereo 
microscope (Olympus SZX16, Pittsburgh, PA). Gentle force was applied onto the 
metal backing against the mold until the stoppers located in adjacent to the shaft array 
hit the mold surface. For needles encapsulating sulforhodamine B, PVA/PVP blend 
was dried at room temperature overnight. For needles encapsulating inactivated 
influenza vaccine, PVA/Sucrose blend was freeze-dried in a lyophilizer (VirTis 
Wizerd 2.0 freeze dryer, Gardiner, NY). The samples were frozen to -40°C for 1 h, 
and then vacuumed at 2.67 Pa at -40°C for 10 h. While the pressure was kept constant 
at 2.67 Pa, the temperature was gradually ramped up to 0°C for 1 h, 20°C for 1 h and 
25°C for another 10 h. After the drying process, the molded pyramidal polymer tips 
connecting to the shaft array were removed from the mold. Prior to inserting 
microneedles into the skin, stoppers in adjacent to the shaft array were bent down. 
   
4.3.2  In Vitro Test 
 
4.3.2.1  Microneedle Insertion and Evaluation 
 
Prior to microneedle insertion, porcine cadaver skin (Pel-Freez, Rogers, AR) was 
processed by removing hair using razors (Dynarex, Orangeburg, NY) and 
subcutaneous fat using a scalpel (Feather, Osaka, Japan). The processed cadaver skin 
was dried with paper towels. The skin was held steadily with a mild tension by two 
fingers. Microneedles were manually pushed against the skin from a distance of 
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approximately 1 cm. To deliver drug by dissolution, the needles were inserted in the 
skin for a designated time. To deliver drug by mechanical separation, manual 
oscillatory shear force was applied onto the needles against the skin immediately after 
insertion. The needles were removed from the skin immediately or waited for a 
designated time after shearing. Each insertion was done in four replicates.  
Human cadaver skin was obtained from the Emory University School of 
Medicine (Atlanta, GA, USA) with approval from the Georgia Tech IRB. To prepare 
human cadaver skin for insertion test, subcutaneous fat was removed by a scalpel. 
Microneedle insertion on human cadaver skin was performed in the same way as was 
done in porcine cadaver skin. To evaluate the damage of metal shafts to human 
cadaver skin, blunt metal shafts without sharp polymer tips were applied against the 
skin in the same manner as were done using microneedles with sharp tips. After 
applying the shafts, the applied region was stained with tissue marking dye (Electron 
Microscopy Sciences, Hatfield, PA) for 5 min. The residual dye was removed from 
the skin surface using paper towels and alcohol swabs (Becton-Dickinson, Franklin 
Lakes, NJ). All images of the microneedles and the application sites on the skin were 
taken using a stereo microscope (Olympus SZX16, Pittsburgh, PA). 
 
4.3.2.2.  Imaging and Histology 
 
Microneedle insertion sites were excised from the bulk skin using a scalpel.  
The isolated skin piece was embedded in Optimum Cutting Temperature (OCT) media 
(Tissue-Tek, Torrance, CA) in a cryostat mold. The sample was fixed by freezing the 
OCT sample on dry ice. Frozen OCT samples were sliced into 12-µm thick sections 
using a cryostat (Cryo-star HM 560MV, Microm, Waldorf, Germany) and imprinted 
on glass slides. Fluorescent images were taken (Nikon E600, Tokyo, Japan) prior to 
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staining. The same skin sections were subject to hematoxylin and eosin staining using 
an automated staining machine (Leica Autostainer XL, Nussloch, Germany). A few 
drops of cytoseal 60 (low viscosity, Richard-Allan Scientific, Kalamazoo, MI) were 
applied onto the stained skin sections. The samples were then covered with glass 
cover slips and dried in fume hood over night. The images of the stained skin sections 
were taken under bright field using the Nikon microscope.     
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4.4  Results 
 
4.4.1  Arrowhead Microneedle Fabrication 
 
Arrowhead microneedles were fabricated by combining two components: 
dissolvable or biodegradable tips encapsulating drug or vaccine, and mechanically 
robust shafts and backing. We first loaded the drug into a PDMS mold (Fig. 4.1A), 
recycled the drug on the mold surface (Fig. 4.1B) and then dried the drug to the tips of 
the mold cavities (Fig. 4.1C). We performed a second mold-filling step by casting 
polymer solution onto the mold. Encapsulation took place as the polymer solution 
mixed with the model drug loaded in the mold cavities (Fig. 4.1D). Next, we removed 
the excess polymer on the mold surface to avoid contact with the metal shafts during 
alignment and drying (Fig. 4.1E).  
Metal shafts were fabricated and prepared separately from the drug loading and 
polymer casting process. After the metal shafts were bent out-of-plane and 
electropolished, we aligned the metal shafts to the mold cavities before the polymer 
dried out. As shown in Fig. 4.1, stoppers located next to the metal shafts prevented the 
shafts from dipping all the way into the bottom of the mold cavities during alignment 
(Fig. 4.1F). The length difference between the shaft and the stopper defined the 
degree of overlap between the shaft and the microneedle tip. After drying, the shafts 
were removed along with the dried polymer tips from the mold (Fig. 4.1G). Finally, 





Fig. 4.1. Schematic of arrowhead microneedle fabrication process. (A) A PDMS mold 
was filled with the drug of interest by vacuum. (B) Excess drug on the mold surface 
was removed and recycled. (C) Drug loaded in the mold cavities was dried by 
centrifugation. (D) Polymer solution was cast into the mold cavities by vacuum. (E) 
Residual polymer solution was spun off by centrifugation. (F) Metal shafts were 
aligned to the mold cavities. (G) The whole device was air-dried at room temperature 
or freeze-dried overnight. After drying, the dried polymer tips connected to the metal 
shafts were removed from the mold. (H) Metal stoppers in adjacent to the shafts 
connected to polymer tips were bent down.   
 
A 5 x 5 array of arrowhead microneedles encapsulating sulforhodamine B was 
fabricated (Fig. 4.2A). The needle shaft’s front dimension was made wider (Fig. 
4.2A1) to offset the mechanically weaker and thinner side of the shaft determined by 
the metal sheet thickness (125 µm) (Fig. 4.2A2). The number of needles in an array 
could be varied. We increased the number of needles to fifty (5 x 10 array) (Fig. 4.2B) 
for inactivated influenza virus encapsulation within the needle tips. The needles 
containing influenza virus appeared to be colorless and opaque (Fig. 4.2B1). 
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Fig. 4.2. Arrowhead microneedles. (A) An array of 5 x 5 arrowhead microneedles 
consisting 600 µm metal shafts capped with 600 µm water-soluble PVA/PVP 
pyramidal tips encapsulating sulforhodamine B (Bar = 1 mm); Individual needle’s 
front view (A1) and side view (A2) (Bar = 300 µm). (B) An array of 10 x 5 arrowhead 
microneedles consisting 700 µm metal shafts capped with 600 µm water-soluble 
PVA/Sucrose pyramidal tips encapsulating inactivated influenza virus (Bar = 1 mm); 
closeup view of individual needles (B1) (Bar = 300 µm). 
 
4.4.2  In Vitro Delivery of Sulforhodamine B in Porcine Cadaver Skin 
 
Next, we evaluated arrowhead microneedle insertion and drug release in porcine 
cadaver skin. After 3 min insertion, sulforhodamine B was barely visible on the skin 
surface (Fig. 4.3A1) but glowed immensely at the inserted spots under fluorescent 
microscopy (Fig. 4.3A2). We believe that majority of the sulforhodamine was 
delivered within the skin but not on the skin surface. We also examined the 
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microneedle insertion from the side by obtaining histological cross sections. We found 
that the microneedle tips (600 µm) were fully inserted into the skin, creating 
approximately 600 µm cavities (Fig. 4.3B1). Drug release from the dissolved 
microneedle tips was local at the insertion cavities (Fig. 4.3B2).  
 
 
Fig. 4.3. Porcine cadaver skin insertions. En face view of skin imaged by bright field 
(A1) and fluorescence (A2) optics (Bar = 1 mm); Histological cross section of a row 
of microneedle insertion sites (B1) and the corresponding fluorescent image of 
sulforhodamine B released from the arrowhead microneedles prior to H&E staining 
(B2) (Bar = 300 µm). 
       
We have already shown that arrowhead microneedles could insert the tips 
completely into the skin. Next, we sought to examine the correlation between the 
length of the needles and the insertion depth in porcine cadaver skin. We kept the 
length of microneedle tip constant at 600 µm while varying the length of metal shaft. 
We investigated three different lengths of microneedles: 900, 1200 and 1500 µm (Fig. 
4.4A, 4.4B, and 4.4C). After insertion, fluorescent images showed local release of 
sulforhodamine at the insertion cavities (Fig. 4.4A1, 4.4B1 and 4.4C1). The H&E 
stained histological cross sections showed cavities generated by the corresponding 
needles in the skin with distinct layers of stratum corneum, viable epidermis and 
dermis (Fig. 4.4A2, 4.4B2 and 4.4C2). Based on the results, we found that although 
longer needles generated deeper insertions, the insertion depths did not match the full 
length of the needles, presumably due to skin deformation.   
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Fig. 4.4. The effect of arrowhead shaft length on porcine cadaver skin insertion depth. 
(A) A 900 µm needle its corresponding insertion depth under fluorescence (A1) and 
H&E staining (A2); (B) A 1200 µm needle and its corresponding insertion depth 
under fluorescence (B1) and H&E staining (B2); (C) A 1500 µm needle its 
corresponding insertion depth under fluorescence (C1) and H&E staining (C2). Bar = 
300 µm 
 
Arrowhead microneedles were capable of delivering drug on the scale of seconds. 
We evaluated two different mechanisms of delivery: The first mechanism involved 
dissolution of the polymer tips. The needles were applied and remained inserted in the 
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skin for subsequent dissolution of the tips by skin’s interstitial fluid. The encapsulated 
drug was released as polymer tips dissolved. A burst release of sulforhodamine up to 
approximately 70% was achieved within 5 s of delivery (Fig. 4.5A). By extending the 
insertion time to 60 s, the delivery efficiency was increased to 90%. The second 
mechanism relied on mechanical separation of polymer tips from metal shafts. Upon 
insertion, an oscillatory shear force was applied to the needles against the skin. With 
one second of administration time after applying the shear force followed by removal 
of the needle backing, the delivery efficiency had reached approximately 90% (Fig 
4.5B). Leaving the needles inserted in the skin longer after shearing did not 
significantly increase the delivery efficiency. As shown in Fig.4.5, both delivery 
approaches were able to achieve high delivery efficiency within seconds.    
 
 
Fig. 4.5. Delivery efficiency of sulforhodamine B in porcine cadaver skin using 
arrowhead microneedles. (A) Dissolution-based delivery over 60 s. (B) Delivery 
facilitated by mechanical shear in seconds. 
      
Arrowhead microneedles also allowed rapid delivery of drug encapsulated within 
materials that are biodegradable (i.e. not dissolvable). Using arrowhead microneedles, 
PLGA needle tips could be rapidly deposited within the skin for controlled release of 



























































process of biodegradation, which could take weeks to months. Rather, the polymer 
tips were mechanically separated from the shafts by shear force upon insertion. As 
oppose to dissolvable tips, the PLGA tip encapsulating sulforhodamine B remained 
physically intact for subsequent controlled release of drug within the skin (Fig. 4.6). 
 
 
Fig. 4.6. Deposition of biodegradable PLGA tips using arrowhead microneedles. (A) 
A 1200 µm arrowhead microneedle encapsulating sulforhodamine B; (B) Histological 
cross section of a PLGA microneedle tip deposited within porcine cadaver skin under 
fluorescent microscopy. (Bars = 200 µm)  
 
4.4.3  Safety Evaluation of Microneedles Post-Insertion 
 
To study the safety of arrowhead microneedles after use, we compared three sets 
of devices: arrowhead microneedles with intact sharp tips, microneedle shafts without 
tips as mimicries of post-insertion needles in which the tips have been dissolved, and 
sharpened shafts as the negative control for skin piercing test. First, we inserted an 
array of 1200 µm tall arrowhead microneedles with sharp polymer tips containing 
sulforhodamine B into human cadaver skin (Fig. 4.7A). The resulting insertion 
showed 50 red sulforhodamine marks on the skin (Fig. 4.7A1). The 
sulforhodamine-dotted skin illustrated that the needles were capable of inserting and 
releasing the drug into human cadaver skin. After insertion, the sharp polymer tips 
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dissolved and left with the blunt metal shafts. To test the safety of used arrowhead 
microneedles, we applied clean blunt metal shafts as the mimicries of post-insertion 
needles onto the skin (Fig. 4.7B). The tissue marking dye did not permeate into the 
skin at the application site (4.7B1). In contrast, if we sharpened the blunt shafts used 
for arrowhead microneedles and applied onto the skin with the same force as applying 
the arrowhead microneedles, the skin was damaged as indicated by dots of 
permeabilized marking dye (Fig. 4.7C and 4.7C1). The study demonstrated that 
arrowhead microneedles become non-sharp after use, thus the needles can not be 




Fig. 4.7. Evaluation of arrowhead needle’s safety in human cadaver skin (A) 1200 µm 
arrowhead needles with exposed 600 µm shafts, and the corresponding insertion (A1); 
(B) Representative 700 µm arrowhead shafts as mimicries of post-insertion needles, 
and the corresponding application of the shafts on the skin stained with tissue marking 
dye (B1); (C) Sharp 700 µm arrowhead shafts with the same aspect-ratio as in (B), 
and the corresponding insertion stained with dye (C1) (Top Row: Bar = 300 µm; 
Bottom Row: Bar = 1 mm). 
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4.5  Discussion 
  
Over the past years, development of microneedles has been progressed at a rapid 
pace to address different drug delivery needs. For the first time, dissolvable or 
degradable microneedle tips containing drug or vaccine can be rapidly separated from 
microneedle backing and remained embedded within the skin upon insertion. The 
backing can then be removed quickly after administration without needing of 
extended patch wearing time. The novelty of arrowhead microneedles including the 
needle’s unique geometry and delivery mechanisms is based in part on the existing 
microneedle designs. For example, arrowhead microneedle shafts supporting the tips 
are made of mechanically robust materials similar to coated microneedle’s substrate, 
except the arrowhead shafts are made blunt. Unlike coated microneedles, the sharp 
edges of arrowhead microneedles are replaced by dissolvable or biodegradable 
materials similar to dissolving polymer microneedles, except the 
dissolvable/biodegradable arrowhead tips are physically spaced apart from the 
microneedle backing by the shafts. 
Microneedles coated with or encapsulating drugs can not achieve reliable and 
consistent delivery simply by disrupting the stratum corneum; these needles have to 
penetrate into the skin with a certain depth for drug release within the tissue. In this 
case, the amount of drug delivered into the skin is largely determined by the depth of 
microneedle penetration. However, variable skin properties pose some challenges in 
achieving a uniform microneedle piercing. Studies have shown that age and regional 
differences account for the variable skin biomechanical properties [149, 150]. 
Although clinical study in human will need to validate the delivery, we believe 
arrowhead microneedles can overcome variable skin properties with the needle’s 
 75
versatile insertion depth. We have shown also arrowhead microneedles were capable 
of delivering drugs into a variety of mammalian skin, including pig cadaver skin, 
human cadaver skin and mouse skin (data not shown). During the skin insertion 
studies, skin deflection was inevitable and the degree of skin deformation was 
dependent on skin properties. Discrepancies between the needle length and its 
corresponding insertion depth in pig skin indicated that additional needle length was 
required to overcome the skin deflection (Fig. 4.4). However, longer needles are 
associated with greater pain [145]. Therefore, a balance between delivery efficiency, 
delivery uniformity and pain needs to be considered.         
Administration time is an important consideration especially when the target 
patient population is large and under time constraints [151]. Conventional transdermal 
patch requires long hours of wearing time due to slow passive transport of drug across 
the skin barrier. Long patch wearing time could generate problems such as premature 
removal of the patch. Literature on dissolving microneedles has reported delivery 
times from minutes to hours for the needles to be fully dissolved [22, 23]. Studies on 
coated microneedles required patch wearing time up to 15 min [16] but needle 
application time as short as one minute has been reported [15]. In our study, 
arrowhead microneedles have shown to deliver drug to porcine cadaver skin as fast as 
one second with over 80% delivery efficiency. The time required to administer drug 
using arrowhead microneedles is comparable to hypodermic needles. This rapid 
administration is favorable in clinical practice when the hospital traffic is severe or 
when conducting a mass vaccination campaign. 
Biohazardous sharp waste continues to pose burdens on public health as well as 
our environment. Arrowhead microneedles solved this problem by using dissolvable 
or biodegradable sharp tips. After administration, these sharp tips become embedded 
within the skin and ultimately were disintegrated and secreted from the body. Without 
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presence of the sharp tips, the microneedle shafts could not easily penetrate into the 
skin. Thus, it is safe to dispose the backing after use without worrying about 
needle-stick injury or sharp waste disposal. 
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4.6  Conclusions 
 
We introduced a novel delivery tool called arrowhead microneedles for rapid 
cutaneous delivery of drug and vaccine. Using arrowhead microneedles, drugs could 
be delivered into the skin via two mechanisms: microneedle tips containing drug 
could be dissolved and then separated from the shafts within the skin. Alternatively, 
the tips could be mechanically separated from the shafts by shear force while 
remaining embedded within the skin. The administration time using arrowhead 
microneedles was on the scale of seconds. After insertion, the needles became dull 
and could not be reused. Therefore, there would be no concerns for biohazardous 
sharp waste disposal or needle-stick injury by the contaminated needles. We envision 
drug and vaccine delivery using arrowhead microneedles can be a safe, quick, 
convenient, patient compliant and potentially self-administered method. 
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5.1  Abstract 
 
To achieve a delivery system that does not require reconstitution of dried vaccine 
when given a vaccination, we incorporated influenza vaccine (A/Puerto Rico/8/34) 
into dissolving microneedles as part of the delivery device. The purpose of this study 
was to investigate the stability of encapsulated vaccine in dissolving microneedles 
during microneedle processing and post-processing storage. We evaluated the effect 
of different drying techniques as well as the effect of formulation on hemagglutination 
(HA) potency of the encapsulated vaccine. After processed into microneedles, the 
encapsulated vaccine was stored at four different temperatures (4°C, 25°C, 37°C and 
45°C) under different packaging conditions. We found that drying the encapsulated 
vaccine by lyophilization maintained the most HA potency. Inclusion of sucrose in the 
formulation also protected the vaccine from drying stresses. The HA assay showed 
that the encapsulated vaccine was more thermally stable than the unprocessed vaccine 
over prolonged periods of time. The finding was consistent with the HA antigenic 
activity measured by ELISA and the virus particle’s morphological structure captured 
using transmission electron microscopy. In conclusion, the encapsulated influenza 
vaccine was more thermally stable than the unprocessed vaccine in solution over 
long-term storage. 
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5.2  Introduction 
 
Influenza is a contagious disease with high morbidity, especially in elderly 
population [152] . Vaccination is the most effective way to prevent and control the 
spread of the disease. Today, almost all influenza vaccines are formulated in liquid 
form, which must be kept at a temperature range of 2°C~8°C to maintain the vaccine 
quality. Due to this narrow temperature requirement, vaccine management typically 
adopts cold chain, a series of temperature control during transport, distribution and 
storage. However, even cold chain does not guarantee the quality of vaccine; any 
accidental exposure to heat or unintentional freezing of vaccines by frozen packs 
during transport and storage can result in vaccine wastage. In addition to the thermal 
instability of liquid vaccine, stock piling of liquid vaccine for the purposes of mass 
distribution and emergency use also requires substantial protection and careful 
handling, and refrigerated warehouse space [153]. 
To minimize the dependency on cold chain and the required storage space, 
vaccines are dried into solid powder form. The most commonly used technique for 
drying vaccines is freeze-dry (lyophilization). Sugar glass technology, an inclusion of 
sugar into vaccine formulation, is used to protect vaccines from freezing stress during 
lyophilization. Amorphous sugar in its glassy state is believed to enhance the stability 
of vaccines by preventing biomolecules from aggregating [112], reducing the 
diffusion and mobility of lipids (vitrification) [113] and replacing water molecules’ 
hydrogen bond interaction with the biomolecules [114]. Current vaccination method 
using needle-syringe system requires reconstitution if the vaccine is dried into powder 
form. However, since reconstitution is an additional preparation step, administration 
error or expiration of reconstituted vaccine can occur if not handle properly [154].   
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Many alternative delivery methods have taken the advantage of more stable dry 
vaccine without needing of reconstitution. Influenza vaccine in powder form has been 
delivered using a needle-free helium-powered PowderJect device into the skin [155]. 
Influenza vaccine can also be delivered intranasally by spraying vaccines into the 
nostrils [156]. Other method involves intradermal delivery of vaccines, which uses 
arrays of microscopic needles that insert vaccines into the epidermis and dermis of the 
skin in a minimally invasive way [117, 118]. Dissolving microneedles, for example, 
deliver molecules of interest by inserting the dissolvable needle tips encapsulating the 
molecules into the skin. Dissolving microneedles have demonstrated the capability of 
encapsulating proteins such as Erythropoietin (EPO), beta-galactosidase, lysozyme 
without causing significant damages to the proteins’ functionalities [21-23]. 
In this study, we encapsulated inactivated influenza virus (A/Puerto Rico/8/34) in 
dissolving microneedles primarily made of polyvinyl alcohol (PVA) and sucrose. PVA 
is a harmless synthetic polymer that has been evaluated in numerous toxicity studies 
[157]. PVA is included in the FDA Inactive Ingredient Guide for topical application, 
transdermal delivery, intramuscular injection, ophthalmic solution, and oral tablet. 
PVA was used as a binder that offers mechanical strength to the microneedles whereas 
sucrose served as a microneedle matrix filler and a vaccine stabilizer. 
The stability of encapsulated vaccine in microneedles at different storage 
temperatures under different packaging conditions was investigated. We first 
evaluated the influence of drying techniques and formulation on vaccine stability 
during encapsulation and processing into microneedles. By following the ICH 
guidelines to carry out post-processing storage for long-term stability studies [95, 96], 
we investigated four storage temperatures: 4°C as the control, 25°C, 37°C as the 
accelerated temperature and 45°C as the stress condition. To determine vaccine 
stability, we assessed the hemagglutination (HA) activity based on the maximum 
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dilution of vaccine that exhibits hemagglutination. We also investigated the antigenic 
activity of HA using capture ELISA. In addition, we used electron microscopy to 




5.3  Materials and Methods 
 
5.3.1  Microneedle Fabrication  
 
5.3.1.1  Microneedle Mold  
 
A polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, Midland, MI) 
microneedle mold was fabricated by Choi et al using photolithography and molding 
techniques [140]. The mold contains 10 x 10 pyramidal microneedle cavities, each 
cavity was measured 600 x 300 x 300 µm (H x W x L). Polylactic acid (PLA) (L-PLA, 
1.0 dL/g; Birmingham Polymer, Pelham, AL) microneedle master structure was made 
by casting molten PLA (195°C) onto the PDMS mold and vacuuming at – 91k Pa for 
3 h. The reverse molded PLA structure was peeled off the PDMS mold after cooling 
to room temperature. New PDMS mold replicates were mass produced by curing 
PDMS mixture on top of the PLA master structure at 37°C overnight. 
 
5.3.1.2  Vaccine and Microneedle Formulation Preparation 
 
Inactivated influenza virus (IIV) (A/Puerto Rico/8/34) was supplied by Emory 
Vaccine Center (Atlanta, GA). The unprocessed vaccine solution was diluted with 
PBS to 0.5 mg/ml. Trace amount of trehalose (D-(+)-Trehalose dehydrate, 
Sigma-Aldrich) was added into the vaccine solution.    
To prepare microneedle formulation, polyvinyl alcohol (PVA) (ACROS Organics, 
MW 2000) was dispersed in DI water at room temperature. The dispersed PVA 
solution was heated to 90°C for 1 h until PVA became fully dissolved. Sucrose 
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(≥99.5%, Sigma-Aldrich) was added into the PVA solution while the solution was still 
warm and mixed uniformly using a spatula. After 1 h of heating, the hot PVA/sucrose 
mixture was centrifuged at 1500 x g for 1 h to remove air bubbles in the mixture. To 
prepare PVA/Sucrose blend containing maltodextrin (dextrose equivalent 4.0 – 7.0, 
Sigma-Aldrich), same procedure was followed except maltodextrin was mixed with 
the PVA solution at 90°C before adding the sucrose. The de-bubbled mixture was 
cooled to room temperature overnight. The formulation used for long-term stability 
study was composed of a mixture of PVA, sucrose, maltodextrin dissolved in DI water 
(ratio 3 : 1 : 0.5 : 4 by weight).       
 
5.3.1.3  Vaccine Loading and Encapsulation   
 
The PDMS molds were loaded with vaccine solution containing trace amount of 
trehalose by vacuuming to – 91k Pa for 3 min. The residual vaccine solution was 
recycled using a pipette. The molds filled with the vaccine were placed in uncapped 
conical tubes (VWR) and were immediately centrifuged (GS-15R, Beckman, 
Fullerton, CA) at 3200 x g at 20°C for 3 min. After centrifugation, the mold surface 
was cleaned by tape stripping (Scotch Tape, 3M, St. Paul, MN). Next, the viscous 
excipient blend was applied onto the molds using a spatula. The molds covered with 
the excipient blend were vacuumed at – 91k Pa for another 5 min. After vacuuming, 
the molds were placed in capped conical tubes and centrifuged at 3200 x g at 20°C for 






5.3.1.4  Drying Process 
 
The mold cast with vaccine and excipient blend were freeze-dried in a 
lyophilizer (VirTis Wizerd 2.0 freeze dryer, Gardiner, NY) for approximately 24 h.  
The freeze-drying steps were programmed as follows: The molds were frozen to 
-40°C for 1 h, and then vacuumed at 2.67 Pa at -40°C for 10 h. While the pressure 
was kept constant (2.67 Pa), the temperature was gradually ramped up to 0°C for 1 h, 
20°C for 1 h and 25°C for another 10 h. After lyophilization, the microneedle array 
was removed from the mold using a double-sided tape (444 Double-Sided Polyester 
Film Tape, 3M, St. Paul, MN). 
 
5.3.2  Microneedle Packaging and Storage 
 
The microneedles were stored under three different packaging conditions. The 
first set of microneedles was placed in beakers without any control of humidity. The 
second set of microneedles was stored in sealed vials with controlled humidity. The 
vial used for microneedle containment consisted of a 3.7 ml uncapped glass vial 
(Fisher Scientific) placed in a 20 ml glass vial (Fisher Scientific). The 3.7 ml vial was 
loaded with 1 g of desiccants (Calcium Sulfate, Drierite, Xenia, OH) to control the 
humidity inside the sealed 20 ml vial. The microneedles were placed in the space 
between the wall of the 3.7 ml vial and the wall of the 20 ml vial. After placing the 
microneedles, the 20 ml vials with desiccants inside were capped tightly and further 
sealed with wrappings of parafilm (Fisher Scientific) around the vial cap. The thrid set 
of microneedles was also sealed in the 20 ml vials with controlled humidity as 
described previously except the air in the vial was replaced by nitrogen gas. The 20 
ml vials containing the microneedles and the desiccants were loosely capped and were 
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repeatedly vacuumed to – 91k Pa and filled with nitrogen gas three times in a vacuum 
desiccator (Pequannock, NJ). All of the microneedles under different packaging 
conditions were allotted to 4°C, 25°C, 37°C and 45°C for long-term storage. Data 
points were collected on Day 0, 1, 3, 7, 14, 30 and 60. 
 
5.3.3  Sample Preparation 
 
Each microneedle array was dissolved in 1 ml of DI water. The dissolved 
microneedle solution containing vaccine and excipients was transferred to an 
eppendorf tube and centrifuged at 29,000 x g (Eppendorf centrifuge 5804) at 4°C for 
30 min. The supernatant was removed and the vaccine pellet was re-suspended with 
PBS to 100 µl. The re-suspended vaccine solution was used for stability analyses. 
 
5.3.4  Characterization of Vaccine Structural Integrity and Antigenic Property 
 
5.3.4.1  Hemagglutination Assay 
 
A total of 100 µl re-suspended vaccine solution was added to the U-shaped 
96-well plate (Corning Costar Corp, Cambridge MA). The control was prepared by 
diluting 1.7 µl of 0.5 mg/ml unprocessed vaccine solution with PBS into 100 µl. The 
vaccine solutions were serially diluted by two-fold with PBS. Chicken red blood cell 
(RBC) (Lampire, Pipersville, PA) was diluted to 0.5 % and added to each well 
containing the diluted vaccine solution (1:1 ratio by volume). After 1 h of incubation 




5.3.4.2  Capture ELISA 
 
Goat-anti Flu H1N1 (USSR strain, from US biological Co.) was used as the 
capture antibody. The antibody was coated on 96-well plates by incubating 100 µl of 
the antibody solution at a dilution of 1:500 in each well overnight at 4°C. The solution 
was aspirated from each well. The plate was washed with PBS-T three times. After 
washing, the plates were blocked by adding 150 µl of PBS containing 2% BSA. The 
plate was incubated at room temperature for 2 h. The 2% BSA solution was aspirated 
and the plate was washed repeatedly. The vaccine samples were obtained from 
re-suspension of the vaccine pellet described previously. One hundred microliter of 
the re-suspended vaccine samples and the unprocessed vaccine standards were 
transferred into the wells and were incubated 2 h at room temperature. After 
incubation, the solutions were aspirated and the plate was washed repeatedly. The 
serum from the influenza HA expressing DNA construct immunized mice was added 
at a dilution of 1:500 to each well. After aspiration and washing, anti mouse IgG-HRP 
(Southern Biotech, Birmingham) was incubated in each well for 1 h at room 
temperature. After washing the plate five times, 50 µl of Tetramethylbenzidine (TMB) 
(Sigma-Aldrich) was added as the substrate solution. Fifty microliter of 0.2N HCl was 
added to stop the reaction. The optical density of each well was determined by a 
microplate reader set at 450 nm. 
 
5.3.4.3  Negative Staining and Electron Microscopy 
 
To examine the morphology of encapsulated vaccine, 10 µl of re-suspended 
vaccine solution was applied to a formvar carbon coated grid at room temperature for 
3 min. Extra vaccine suspension was absorbed by filter paper. The grids were 
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immediately stained with 2% phosphotungstic acid for 30 sec. Excess stains were 
removed by filter paper. The samples were examined on a Hitachi 7500 transmission 
electron microscope.  
 89
5.4  Results 
 
5.4.1  Microneedle Fabrication 
 
To investigate the stability of vaccine encapsulated within dissolving 
microneedles, unprocessed vaccine was reformulated and dried into microneedles.  
Fig. 5.1 showed a 10 x 10 array of solid dissolving microneedles made of 
PVA/Sucrose blend encapsulating influenza vaccine. The back side of the array was 
immobilized on a double-sided tape for the ease of handling and portability. Each 
pyramidal needle was 600 µm tall with a 300 x 300 µm base (Fig 5.1B). The needles 
encapsulating vaccine appeared to be opaque. Although not visually distinguishable, 
the vaccine was encapsulated only within the microneedles but not in the array 
backing. 
   
 
Fig. 5.1. Dissolving microneedles encapsulating inactivated influenza virus. (A) A 10 





5.4.2  Effect of Microneedle’s Drying Methods on HA Potency 
 
We sought to select a drying method that maintains the most HA potency after 
microneedle processing. Microneedles containing influenza vaccine were subject to 
three different drying methods including lyophilization, thermal dry at 25°C and at 
45°C. According to Fig. 5.2, microneedles dried by lyophilization maintained an 
average of 80% HA potency relative to the unprocessed vaccine at 4°C. The drying 
processes involving evaporation of water from the microneedles by heat at 25°C and 
45°C caused approximately 50% and 55% loss of HA potency respectively. 
Lyophilization was able to maintain the highest HA potency compared to thermal 
drying method at 25°C and 45°C (Student’s t-test, p<0.05). Due to the difference 
between each drying method’s water removal rate and drying mechanisms, the 
resulting residual moisture in the microneedles might vary. To investigate if the 
residual moisture in the microneedles would have further effect on the HA potency, 
we stored all of the microneedles dried by different methods in separate sealed glass 
vials containing desiccants for five days at room temperature. The moisture content of 
all the microneedles should have reached equilibrium with the desiccant-controlled 
environment. The result showed that there was no significant difference of HA 
potency between microneedles that were immediately fabricated and microneedles 































Fig. 5.2. Effect of microneedle fabrication drying process on HA activity. Day 0 
indicates the dried microneedles immediately after fabrication. Day 5 indicates the 
microneedles stored in sealed containers with desiccants at 25°C over five days. (N = 
4) 
 
5.4.3  Effect of Formulation on HA potency 
 
The goal was to determine the most appropriate formulation composition for 
stable vaccine encapsulation and microneedle fabrication. The formulation used in 
this study primarily consisted of PVA and sucrose. By varying the ratio of these two 
excipients, we aim to determine the effect of formulation composition on HA potency. 
The formulation containing only PVA led to 80% loss of HA potency when 
lyophilized with the encapsulated vaccine (Fig. 5.3). Inclusion of 33% sucrose in the 
formulation resulted in a significant recovery of the HA potency up to approximately 
70%. Further increment of sucrose in the formulation did not significantly increase 
the HA potency (ANOVA, p>0.05). Hence, the presence of sucrose was critical but 
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Fig. 5.3. Effect of formulation on HA activity. Each bar shows a different formulation 
composition consisting PVA and/or sucrose dissolved in DI water. (N = 4) 
 
5.4.4  Stability of Encapsulated Vaccine in Dry State versus Unprocessed 
Vaccine in Wet State at Various Temperatures 
 
We hypothesized that vaccine formulated into dry state is more stable than 
unprocessed vaccine in wet state. To test this hypothesis, we reformulated and 
processed vaccine into solid dissolving microneedles and stored at 4°C, 25°C, 37°C 
and 45°C over extended periods of time. A set of unprocessed vaccine solutions was 
allotted and stored in parallel with the processed vaccine samples at those four 
temperatures. The unprocessed vaccine stored at 4°C (control) remained stable 
throughout the entire study. The processed encapsulated vaccine maintained 
approximately 60% HA potency over 4 weeks, even with those samples subject to 
elevated temperatures. There was no significant HA potency difference among the 
encapsulated vaccine groups stored at different temperatures within 4 weeks 
(One-way ANOVA, p>0.05). On the other hand, the unprocessed vaccine stored 
outside of refrigeration showed a dramatic HA potency drop within a few days. Based 
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on the long-term stability study shown in Fig. 5.4, the encapsulated vaccine processed 
into dried microneedles was significantly more stable than the unprocessed vaccine in 


































Fig. 5.4. Comparison of the long-term stability of unprocessed vaccine solutions 
versus dried microneedle vaccine samples based on HA potency under different 
temperatures. MN indicates the processed vaccine encapsulated within microneedles. 
WET indicates the unprocessed vaccine in solution. (N≥3) 
 
5.4.5  Effect of Different Packaging Conditions on Encapsulated Vaccine 
Stability 
 
To answer the question of whether the stability of encapsulated vaccine was 
influenced by different packaging condition over the long term, we stored the 
microneedle samples encapsulating the vaccine under three packaging conditions.  
Microneedles were placed in open containers without any control of humidity (N), or 
in sealed containers with controlled humidity by desiccants (D), or in sealed 
containers filled with nitrogen gas and with controlled humidity by desiccants (DV).  
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Fig. 5.5 showed that the HA potencies of all encapsulated vaccine stored in three 
packaging conditions were equivalent and remained unchanged relative to the freshly 
fabricated microneedles on Day 0 throughout 8 weeks at 25°C (One-way ANOVA, 


























Fig. 5.5. Comparison of the long-term stability of dried microneedle vaccine samples 
stored under different packaging condition. N: Open containers without any control of 
humidity. D: Sealed containers with controlled humidity by desiccants. DV: Sealed 
containers filled with nitrogen gas and with controlled humidity by desiccants. (N≥3) 
 
5.4.6  Antigenic Properties of Encapsulated Vaccine and Unprocessed Vaccine 
under Different Thermal Stresses 
  
We used a different approach, the capture ELISA, to validate the stability of 
encapsulated vaccine and unprocessed vaccine at different temperatures based on the 
HA’s antigenic property. Vaccine encapsulated in microneedles and unprocessed 
vaccine solutions were stored in parallel at 4°C, 25°C, 37°C and 45°C over a period 
of 2 weeks. We found that the unprocessed vaccine stored over 2 weeks outside of 
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refrigeration (25°C, 37°C and 45°C ) resulted in a four-fold loss in HA binding 
activity against Goat-anti Flu H1N1 antibody. On the contrary, the encapsulated 
vaccine, even with the ones exposed to elevated temperatures for 2 weeks, showed 






















Fig. 5.6. Evaluation of vaccine stability over 2 weeks using capture ELISA. Left: 
Microneedle samples (MN) containing encapsulated vaccine stored at 4°C, 25°C, 37°C 
and 45°C. Right: unprocessed vaccine solution (C) stored at 4°C (control), 25°C, 37°C 
and 45°C. (N≥3) 
 
5.4.7  Morphology of Inactivated Influenza Viruses under Different 
Temperatures 
 
We further examined the stability of encapsulated vaccine and unprocessed 
vaccine at different temperatures based on the morphological integrity of virus 
particles. The virus particles collected from dissolved microneedle solution and 
unprocessed vaccine solution were negatively stained with 2% phosphotungstic acid 
and examined under electron microscope. As shown in Fig. 5.7, the encapsulated 
vaccine stored at 4°C, 25°C, 37°C and 45°C (Fig 5.7A) as well as the unprocessed 
vaccine stored at 4°C vividly showed intact virus particle structure with a circular 
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contour of lipid bilayer. The integrity of the encapsulated virus particles was 
maintained even under elevated temperatures for 2 weeks. On the other hand, the 
unprocessed vaccine stored at 25°C, 37°C and 45°C showed ruptured or swollen 
particle structures (Fig 5.7B). The lipid bilayer of those unprocessed virus particles 
subject to elevated temperatures was not distinctively visible compared to that of the 




Fig. 5.7. Images of electron microscopy of negatively stained inactivated influenza 
virus particles stored at different temperatures. (A) The encapsulated virus particles 
dissolved off the microneedles stored at 4°C, 25°C, 37°C and 45°C maintained intact 
particle morphology with visible lipid bilayer structures. (B) The unprocessed virus 
particles stored at 4°C kept an intact morphology while all other unprocessed virus 




5.5  Discussion 
 
While most lyophilized vaccine powder requires reconstitution for injection, 
some delivery systems have taken the advantage of dried vaccine for immunization.  
One example is the use of solid microneedles to deliver dried vaccine into the skin 
[117, 118]. Differ from other microneedle systems, dissolving microneedles 
encapsulate drugs and biomolecules within the needle matrix [22, 23, 76]. In most 
cases, fabrication of dissolving microneedles requires water removal, a step that 
exposes the molecules to drying stress. Therefore, we evaluated three drying 
approaches: lyophilization, thermal dry at 25°C and at 45°C. The results showed that 
the lyophilization maintained the most HA potency compared to all other methods 
attempted. Although lyophilization may associate with higher cost as it requires more 
sophisticated equipment and drying time from hours to days, the overall cost may be 
lower if vaccine is batch processed and if the process results less vaccine wastage due 
to damage from the drying stress. 
Formulation played a critical role in vaccine stability. Adoption of sugar glass 
technology has been described in literatures for protecting proteins, liposomes and 
viruses from drying stresses [106-108, 110, 111]. Similarly, our formulation 
containing PVA and sucrose also protected the vaccine from freezing stress during 
lyophilization. The formulation was able to maintain a long-term stability of the 
vaccine at various temperatures. Although inclusion of sugars have shown to enhance 
the stability of biomolecules, crystallization of sugars can cause damage to the 
vaccine antigens if the sample is not properly dried [88]. According to Fig. 5.3, 
addition of merely 33% sugar recovered almost all HA potency. Based on this finding, 
we did not use formulations that have a dominant presence of sugars for the long-term 
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stability studies to avoid crystallization of sugars.   
One of the obstacles of performing HA assay with the dissolved microneedle 
solution was the presence of PVA. PVA interfered with the HA assay by promoting 
RBC precipitation. To overcome this problem, we separated the vaccine from the 
polymer in the dissolved microneedle solution by centrifugation. The virus particles 
were heavier enough to be spun down while PVA and other excipients remained 
suspended in solution. We collected the pellets and re-suspended into aqueous 
samples for the assays. In this way, the reduced presence of PVA in the re-suspended 
vaccine samples greatly minimized the assay interference. But another issue arose as 
we applied high centrifugal force to the vaccine. We found that unprocessed vaccine 
under high speed centrifugation lost as much as eight-fold HA potency (data not 
shown). However, addition of the microneedle excipients (i.e. PVA and sucrose) to 
unprocessed vaccine rescued the HA potency loss from the centrifugal damage. We 
hypothesize that these excipients might form a coating on the virus particles; these 
coatings prevented the virus particles from aggregating and reduced non-specific 
interaction with the container surface promoted by the centrifugal force.   
According to Fig. 5.4, HA potency of all the encapsulated vaccine samples 
remained unchanged for at least four weeks under all storage temperatures (4°C, 25°C, 
37°C and 45°C), whereas unprocessed vaccine solutions subject to elevated 
temperatures lost all HA potency within a few days. It was clear that the encapsulated 
vaccine in dry state was more resistant to thermal variation than the unprocessed 
vaccine. One question that may arise is the discrepancy of HA potency between the 
encapsulated vaccine immediately after microneedle processing and the unprocessed 
vaccine at 4°C on Day 0 (the control). We proposed several explanations to address 
this question. We believe that the drying process might cause some damage to the 
vaccine due to freezing and drying stresses. As mentioned earlier, centrifugation led to 
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a dramatic HA potency loss of the unprocessed vaccine. Even though adding PVA and 
other excipients secured the vaccine from significant damage, some loss (0~50%) was 
still seen (data not shown). We might also lose some vaccine as we isolated the 
vaccine pellet by removing the supernatant. Moreover, throughout the whole 
microneedle dissolution and solution transfer processes, the chance of non-specific 
interaction of the vaccine with the container surfaces was also increased.  
We did not observe any difference in the encapsulated vaccine stability stored 
under different packaging conditions. Insensitivity of vaccine stability to packaging 
condition is advantageous because accidental damage to the package containing 
microneedles, or opened package prior to use would not raise concerns for instant loss 
of stability. However, proper packaging is still important to keep moisture and 
physical damage away from the microneedles. 
Potent stability of encapsulated vaccine in dissolving microneedles offers many 
benefits to modern vaccination. Reduced sensitivity of encapsulated vaccine to 
thermal variation decreases the reliance on cold chain, which in turn could save cost 
associated with refrigerated equipment, facilities and personnel. By drying vaccine 
into solid microneedles, warehouse storage space and weight associated with transport 
cost are greatly minimized. Transport vaccines to developing countries where hot 
climate is common would benefit from this potent stability by encapsulating vaccines 
within microneedles. 
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5.6  Conclusions 
 
We have evaluated the stability of encapsulated vaccine during microneedle 
fabrication and post-microneedle processing. Drying by lyophilization maintained the 
most vaccine stability. Inclusion of sucrose in the formulation also minimized the HA 
potency loss during microneedle processing. Three techniques including HA assay, 
capture ELISA and TEM have validated the potent stability of encapsulated vaccine 
over their unprocessed vaccine counterparts outside of refrigeration for extended 
periods of time. Furthermore, the encapsulated vaccine stability was independent of 
the packaging conditions we studied. The potent stability of encapsulated vaccine 
offered by solid microneedle dosage form could potentially reduce the dependency of 
cold chain, eliminate the need of reconstitution, require less storage space and allow 
higher portability. 
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6.1  Abstract 
 
Current vaccination largely relies on injection using hypodermic needles. This 
method of administration has low patient compliance, produces sharp biohazardous 
waste after use and requires highly trained personnel. In this study, arrowhead 
microneedles were used to administer inactivated influenza vaccine (IIV) (A/Puerto 
Rico/R/8/34) (H1N1) rapidly into the skin. We aimed to find out if cutaneous delivery 
of IIV using arrowhead microneedles elicits comparable immune response to the 
intramuscular injection using hypodermic needles. We delivered a dose of 10 µg IIV 
to Balb/C mice. The results showed that cutaneous delivery using arrowhead 
microneedles induced statistically comparable levels of antibody responses against 
influenza virus to intramuscular injection after a single immunization. Microneedle 
immunization protected all the mice from lethal challenge with homologous influenza 
virus (PR8), while 67% mice were protected from challenge with heterologous 
influenza virus (WSN). In sum, arrowhead microneedles could administer IIV into the 
skin rapidly within one minute and induced potent immune responses that protected 
the mice from lethal challenges. Unlike hypodermic needles, arrowhead microneedles 
do not generate sharp biohazardous waste and can potentially be self-administered.  
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6.2  Introduction 
 
Skin offers an attractive route for drug and biopharmaceutical delivery due to the 
avoidance of first-pass effect. Abundant presence of antigen presenting cells in the 
epidermis and dermis layer of the skin also serve as excellent vaccine delivery targets 
for triggering immune responses [158]. However, challenges for transdermal delivery 
lie upon the skin’s outermost layer, stratum corneum, which prevents highly 
hydrophilic drugs and macromolecules from entering into the body [3]. To circumvent 
this skin barrier, hypodermic needles administer vaccines by penetrating deeply into 
tissues or muscles. More targeted delivery of vaccines to the skin is feasible by using 
the Mantoux technique, but this method requires highly trained personal [159]. 
Another approach for targeted vaccine delivery to the skin is to use miniaturized 
hypodermic needles with limited exposed length that only penetrate a certain depth 
into the skin [116, 134]. Apart from the most widely used hypodermic needles, 
bifurcated needles, the fork-like metal needles, have also been used to deliver 
smallpox vaccine by repeatedly jabbing the skin [160-162]. Either use of hypodermic 
or bifurcated needles cause pain and produce sharp biohazardous waste after use. 
Moreover, re-using and sharing of these needles pose the risk of blood-borne 
pathogen disease transmission. 
Many alternative delivery methods aim to administer vaccines across the skin in 
a less invasive way. Immunization by physical perturbation of stratum corneum using 
tape stripping technique has shown to enhance antibody response compared to 
hydration of the skin alone [130]. Immunization by electrical means has been 
demonstrated using electroporation to enhance DNA vaccine delivery across the skin 
[163, 164]. Miniaturized needle structure measured in micron-size, also known as 
microneedles, have also induced potent immune responses in mice by delivering 
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coated vaccines into the skin [117, 118]. Building upon many years of technological 
advancement of microneedles [15, 16, 19, 20, 23, 63], we have designed a new type 
of microneedles called arrowhead microneedles for drug and vaccine delivery. 
Arrowhead microneedle’s sharp tips dissolve upon insertion into skin while the 
remaining dull shafts and backing can be removed from the skin quickly without 
producing sharp waste.  
The goal of this study was to compare the immune responses of cutaneous 
delivery using arrowhead microneedle with intramuscular administration of IIV using 
hypodermic needles in Balb/C mice. We hypothesized that cutaneous immunization 
using microneedles would generate comparable immune responses to intramuscular 
immunization. We also hypothesized that single immunization using microneedles at a 
dose of 10 µg IIV could protect mice from lethal challenge by the homologous virus 




6.3  Materials and Methods 
 
6.3.1  Inactivated Influenza Virus Preparation 
 
Influenza virus (A/Puerto Rico/R/8/34) (H1N1) were inoculated and grown in 
embryonated chicken eggs. Three days post-inoculation, the allantoic fluid was 
harvested from the infected eggs. Harvested allantoic fluid was then concentrated with 
Quick-stand filtration system and purified with ultracentrifugation through 
discontinuous sucrose gradient. The virus used for immunization was inactivated with 
0.1% formalin for 3 days at 4°C. After inactivation, the purified virus was 
characterized by SDS-PAGE and western blot to examine the presence of specific 
proteins. Hemagglutination (HA) assay was performed to evaluate the function and 
integrity of hemagglutinin proteins. The virus was also negatively stained with 2% 
phosphotungstic acid to check the virus morphology under an electron microscope 
(Hitachi 7500, Japan).  
 
6.3.2  Microneedle Fabrication and Inactivated Influenza Virus Encapsulation 
 
Arrowhead microneedles were fabricated as described previously in Chapter 4: 
“Rapid cutaneous delivery using arrowhead microneedles”. For immunization study, 
10 µg IIV containing a trace amount of trehalose was loaded into a 
polydimethylsiloxane (PDMS) mold. For in vivo insertion test, sulforhodamine B was 
used for visual inspection of the insertion spots on mouse skin. An excipient blend 
consisting polyvinyl alcohol (PVA) and sucrose (1:1 ratio by weight) dissolved in DI 
water was cast onto the mold by vacuum and centrifuge. Arrays of fifty 700 µm tall 
stainless steel shafts (5 x 10) was aligned to the PDMS mold cast with excipient blend, 
and then freeze-dried overnight. After drying, the dried excipient blend connected to 
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the metal shafts was removed from the PDMS mold, forming arrowhead 
microneedles.  
 
6.3.3  In Vivo Insertion Test 
 
Prior to the immunization study, in vivo assessment of microneedle insertion on 
mouse skin was performed following the Institute for Animal Care and Use 
Committee (IACUC) guidelines. Female Balb/c mice were purchased from Charles 
River Laboratory and housed at the Georgia Tech Physiological Research Laboratory. 
The mice were anesthetized in a chamber filled with 5% isofluorance with an oxygen 
feed rate at 1000 ml/min. The mice were transferred from the chamber to a warm 
procedure stage immediately when they lost consciousness. The mice’s noses were 
covered with rubber masks flowing 2% isofluorane with an oxygen feed rate at 400 
ml/min. The hair on the backside of the mice was fist removed gently by a clipper. 
Then, the depilatory cream (Nair) was applied onto the shaved region for 3 min and 
excess Nair was wiped away with wet gauzes. The step of applying and removing 
Nair on the skin was repeated two to three times for complete removal of the hair at 
the desired insertion site. After the hair was removed, approximately 1.5 cm x 1.5 cm 
nude skin was pinched onto a flat surface. Microneedles were inserted perpendicularly 
to the nude skin for specified time durations. Images of the inserted skin were taken 
using a stereoscope (Olympus SZX16, Pittsburgh, PA). While the mice were still 
unconscious under anesthesia, they were euthanized in a CO2 chamber in accordance 










Fig. 6.1. Single immunization timeline. Week 0: Mice (six per group) were 
immunized by intramuscular injection and cutaneous microneedle insertion. Week 2, 
3 and 4:  Blood samples were collected retro-orbitally for antibody serum and HAI 
analyses. Week 4: After collecting the blood samples, the mice were challenged by 
mouse-adapted PR8 and WSN viruses. Week 6: The mice were sacrificed and blood 
samples were collected.   
 
For the immunization study, mice were divided into four groups: (i) 
Intramuscular injection of PBS using hypodermic needles (control); (ii) Intramuscular 
injection of IIV; (iii) Intramuscular injection of IIV dissolved off the microneedles; 
And (iv) cutaneous insertion using microneedles. Each mouse was given a dose of 10 
µg IIV.   
 
6.3.5  Immunization of Mice  
 
Female Balb/C mice (6-8 weeks old) were purchased from Charles River 
Laboratories and housed at the Emory University animal facility in micro-isolator 
cages. For intramuscular immunization, 10 µg IIV suspended in 100 µl PBS was 
injected into mouse quadriceps. For cutaneous immunization by arrowhead 
microneedles, the hair on the back of the mouse was removed by depilatory cream 
Week 0         Week 2   Week 3   Week 4            Week 6 
Immunization 
(dose: 10 µg)  
Blood sample collection  
Challenge by 
mouse-adapted PR8 
and WSN (100 LD50) 




(Nair) and washed with 70% ethanol one day before the immunization. Prior to 
microneedle insertion, the mice were anesthetized by Ketamine and Xylazine. 
Approximately 1.5 cm x 1.5 cm skin was pinched onto a flat surface and the 
microneedle array was pressed perpendicularly to the skin for 1 min.  
 
6.3.6  ELISA and Hemagglutination Inhibition Assay 
 
 Blood samples were drawn retro-orbitally from mice on day 14, day 21 and day 
28 post-immunization and 2 weeks after the lethal challenge.   
ELISA assay was performed following the established protocol to measure the 
presence of influenza hemagglutinin (HA) specific antibodies in individual mouse 
sera [165]. Briefly, purified His-tagged HA proteins were used as the coating antigens. 
Standard curve was generated by coating each ELISA plate with serial two-fold 
dilutions of purified mouse antibodies with known concentration. The concentrations 
of influenza HA specific antibodies in serum samples were calculated by using the 
established standard curves.  
The paired samples were tested together by hemagglutination inhibition (HAI) 
assay following established protocols [166]. The sera were treated with 
receptor-destroying enzyme (RDE) (Kenka Seiken, Tokyo, Japan) (I:3) at 37°C 
overnight to remove nonspecific inhibitors. The residual RDE was destroyed by heat 
inactivation at 56°C for 30 min. Serial two-fold dilutions of RDE-treated serum (1 in 
10) were titrated in a 96-well microtiter plate (Corning Costar Corp, Cambridge MA) 
against 4 hemagglutinin units of reference antigens (H1N1) using 0.25% chicken 
erythrocytes (Lampire, Pipersville, PA). After 45 min of waiting, the HAI titer was 




6.3.7  Lethal Virus Challenge 
 
Live influenza virus challenge was conducted in a BSL+ animal facility. Four 
weeks after immunization, mice were challenged under light anesthesia by intranasal 
instillation with 100 x LD50 of mouse-adapted influenza virus A/PR/8/34 diluted in 
50 µl PBS. After the challenge, mice were monitored for weight change and signs of 
illness on a daily basis. Mice that exhibited severe sighs of illness and significant 
weight loss (>25%) were euthanized in accordance with IACUC. At the end of the 
challenge study, mice that survived the challenge were sacrificed and blood samples 
were collected for post-immunization analyses. 
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6.4  Results 
 
6.4.1  In Vivo Arrowhead Microneedle Insertion Test 
 
Prior to immunizing the mice, we wanted to demonstrate the capability of 
encapsulating IIV into arrowhead microneedles and successfully inserting the needles 
in vivo. Arrowhead microneedles were fabricated by capping sharp dissolvable tips 
onto mechanically robust metal shafts (Fig. 6.2A). The tips of the arrowhead 
microneedles were made of PVA/sucrose blend. These needles dissolved upon 
insertion into skin,and produced no sharp biohazardous waste. Each microneedle had 
an overall length of 1.3 mm, consisting of a 600 µm tall pyramidal tip supported by an 
800 µm shaft with 100 µm overlap (Fig. 6.2B). The microneedles encapsulating IIV 
appeared colorless and opaque. For visual inspection, we incorporated 
sulforhodamine B into the needles to show the encapsulation of molecules within the 
microneedles and the insertion on the skin (Fig. 6.2C, 6.2D). The microneedles 
encapsulating sulforhodamine B were inserted into the skin of an anesthesized mouse 
for 1 min. The microneedle tips dissolved and released sulforhodamine B into the 




Fig. 6.2. An array of 10 x 5 arrowhead microneedles: (A) Encapsulating IIV; (B) Side 
view; (C) Encapsulating sulforhodamine B; And (D) insertion into mouse skin in vivo. 
Bar = 1 mm 
 
6.4.2  Induction of Antibody Responses by Cutaneous Delivery of IIV Vaccine 
using Microneedles 
 
The goal was to compare the immune responses induced by cutaneous 
delivery of IIV vaccine using arrowhead microneedle (MN) with those induced by 
intramuscular (IM) injection. Blood samples were collected at 2 weeks, 3 weeks and 4 
weeks post immunization and analyzed for antibody responses against the HA protein 
and the HAI titers against the inactivated influenza virus. As shown in Fig. 6.3A, 
cutaneous delivery of IIV vaccine using MN induced comparable levels of antibody 
responses against homologous influenza virus to IM injection 4 weeks after a single 
immunization. While the average antibody responses induced by microneedles 
appeared lower than that obtained by intramuscular injection, the difference was 
statistically insignificant (student’s t-test, p>0.05). High antibody responses were 
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elicited in all immunized groups against PR8 antigens. Intramuscular injection of IIV 
dissolved off the microneedles induced similar levels of antibody responses compared 
to other groups (student’s t-test, p<0.05), indicating that the immunogenicity of IIV 
remained unchanged during microneedle encapsulation and drying process. We 
further analyzed the HAI titers induced by different immunization approaches. As 
shown in Fig. 6.3B, HAI activity was detected in all vaccinated groups and the HAI 
levels were in direct correlation with the level of antibody responses against HA 




Fig. 6.3. Comparison of induced antibody responses 4 weeks after immunization. 
Eight groups of mice were immunized, six mice per group. Mice were immunized by 
microneedles (MN), intramuscular injection (IM), intramuscular injection of IIV 
dissolved off the microneedles (Redis) and intramuscular injection of PBS (control). 
(A) The serum antibody levels against HA proteins were measured by ELISA. (B) 













































6.4.3  Protection of Mice against Lethal Influenza Virus Challenge with a Single 
Immunization of IIV Vaccine 
 
Based on the strong antibody responses induced by cutaneous delivery of IIV 
using microneedles after a single immunization, we aimed to test whether single 
immunization could protect mice against lethal virus challenge. At week 4 
post-immunization, mice were challenged with 100 LD50 of mouse-adapted 
homologous influenza virus (PR8) and heterologous virus (WSN). As shown in Fig. 
6.4, while all of the mice in the control groups succumbed to challenge and were 
sacrificed between days 5 and 8 post-challenge, all mice immunized by microneedles 
encapsulating the IIV or intramuscular injections protected the mice from the lethal 
challenge with PR8. Although all of the experimental groups showed as much as 20% 
weight loss when infected with the heterologous virus WSN, intramuscular injection 
of IIV and IIV dissolved off the microneedles gave full protection to all the mice. 
Immunization using microneedles protected 4 out of 6 mice, or 67% survival rate of 





Fig. 6.4. Change of mouse weight over two weeks after lethal challenges. (A) Four 
groups were challenged by homologous virus strain (PR8); (B) Another four groups 
were challenged by heterologous virus strain (WSN). Each group consisted of 6 mice. 
A dose of 10 µg IIV was given to each mouse. Mice were immunized by microneedles 
(MN), intramuscular injection of IIV (IM), intramuscular injection of IIV dissolved 
off the microneedles (Redis) and intramuscular injection of PBS (control). Mice were 

















































Fig. 6.5. Survival rate of mice after lethal challenges. Mice were monitored for 
additional two weeks of their protection against infection of (A) homologous strain 
(PR8), (B) heterologous strain (WSN). Mice were immunized with a dose of 10 µg 
IIV by microneedles (MN), intramuscular injection (IM), intramuscular injection of 
IIV dissolved off the microneedles (Redis), and intramuscular injection of PBS 














































6.5  Discussion 
 
It is advantageous to administer drug or vaccine rapidly and effectively, 
especially in the situation where time is limited and traffic of patients is severe. To 
achieve a rapid, effective and safe delivery, we introduced a new type of dissolving 
microneedles called arrowhead microneedles. The key advantage of dissolving 
microneedles is the disappearance of the sharp needle tips after administration. For 
the first time, in vivo delivery using dissolving microneedles could be completed 
within one minute. The enhanced delivery rate was achieved by adopting two 
strategies. The first strategy involved the enhancement of dissolution rate of the 
microneedle tips. We incorporated a highly water-soluble excipient, sucrose, into the 
formulation while reducing the presence of less soluble polyvinyl alcohol. Even 
though microneedles made solely of sucrose could dissolve even more readily, poor 
mechanical property of sucrose prevented the needles from inserting reliably into the 
skin. The second strategy was to insert the needles fully into the skin. Differ from 
other existing dissolving microneedles in which the needle tips are connected to the 
backing, arrowhead microneedle tips are spaced apart from the backing by elongated 
shafts. This extension of needles by the shafts allowed complete insertion of the 
needle tips into the mushy mouse skin. Complete embedment of the needle tips 
maximized the area of contact with the moisture in the skin tissue, thereby allowed a 
faster dissolution. 
 The antibody level against homologous influenza virus induced by cutaneous 
immunization using arrowhead microneedles was statistically commensurate with the 
intramuscular injection using hypodermic needles. However, the average antibody 
level appeared lower for the microneedle immunization. Similar trend was also 
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observed from the HAI titer. We believe the lower averages were due to lower 
delivery efficiency. We have observed that more consistent delivery around 90% was 
achieved in pig cadaver skin, whereas in vivo delivery in mice resulted more variable 
delivery ranged from 60% to 90% (data not shown). Due to improper insertions of the 
needle arrays into the mice, two mice had shown extraordinary low antibody titers, 
which were reflected in the challenge study by the heterologous strain (WSN). Two 
mice died in the challenge, while other mice with comparable antibody titers to the 
intramuscular injection groups stayed alive. 
Due to the difficulty of inserting a microneedle array measured approximately 1 
cm x 1 cm into a limited surface area of a mouse skin, we offer some 
recommendations for improvements on in vivo insertion of microneedle array into 
mice. 
 
1. Identify regions where the skin is easy to stretch without over jamming the mouse 
body. 
2. Fully anesthetized the mice during the entire course of administration. Any animal 
movement can disrupt the insertion, especially for small animals like mice whose 
skin has to be stretched intensively for delivery. 
3. The mouse hair on the site of microneedle insertion must be removed thoroughly. 
Residual hair can impede the microneedles from penetrating into the skin. The 
area of depilation also has to be large enough to accommodate the entire 
microneedle array. Additional depilated area is preferred because pinching a piece 
of nude skin for microneedle insertion can not always be right on the target; larger 
depilated area eases the effort to aim the microneedles to the depilated skin site. 
4. Prior to microneedle insertion, the microneedles must be stored and packaged 
properly. Since dissolving microneedles are made of water-soluble excipients, 
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many excipients are hygroscopic by nature. Prolonged exposure to high moisture 
environment such as inside refrigerator or in the basement with high humidity can 
weaken the mechanical properties of the microneedle’s dissolvable tips. The 
surface of the animal skin also has to be dried completely to prevent premature 
dissolution of microneedles before insertion. 
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6.6  Conclusions 
 
We encapsulated inactivated influenza virus within arrowhead microneedles for 
cutaneous immunization in mice. The results showed that cutaneous delivery using 
arrowhead microneedles induced statistically comparable levels of antibody responses 
against influenza virus to intramuscular injection after a single immunization.  
Microneedle immunization protected all the mice from lethal challenge by 
homologous influenza virus (PR8), while 4 out of 6 mice were protected from 
challenge by heterologous influenza virus WSN. Based on the results, arrowhead 
microneedles were able to administer vaccine rapidly and induced immune response 
effectively. The microneedles can serve as a patient compliant and potentially 
self-administered tool for future vaccine delivery. 
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Dissolving microneedles offer great promise to the next generation of drug and 
vaccine delivery across the skin as an alternative to hypodermic needles. The 
following discussion is devoted to the technical details regarding dissolving 
microneedle fabrication, delivery to skin, formulation, stability of encapsulated 
vaccine, in vivo immunization, and future directions of dissolving microneedles. 
 
7.1  Mass Fabrication of Microneedles 
 
Three basic steps of dissolving microneedle fabrication developed in this project 
include drug loading into a mold, casting water-soluble excipients and drying the 
microneedles. 
Drug loading is critical from the manufacturing cost point of view. Many drugs 
or vaccines are expensive and time consuming to produce. Therefore, the drug loading 
process has to be efficient with minimal wastage. Ideally, all drug intended for 
delivery has to be completely loaded into the tips of the microneedle mold. Any 
residual drug remaining on the mold surface during fabrication would end up in the 
microneedle backing and is therefore considered wasted. When mass producing the 
needles, if drug wastage is not carefully controlled, the amount of wastage can add up 
to a significant loss. Drug encapsulated in the backing has very limited access into the 
skin due to the following reasons: First, the size of the molecules might be too large to 
passively diffuse across the non-inserted portion of the skin where the stratum 
corneum is intact. Second, the interstitial fluid from the skin might not provide 
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enough moisture to wet the backing. As a result, the backing may not be permeable 
enough for the drug to diffuse into the skin. Last, the skin might reseal itself before all 
the drug gets into the skin. 
To fabricate dissolving microneedles, it takes some time for the microneedle 
matrix materials (i.e. polymer solution) to dry. During the process of drying, the 
encapsulated drug in theory can freely diffuse within the microneedle matrix made of 
polymer solution. We found that concentrated polymer solution with less water 
content, higher viscosity and thereby lower diffusivity prevented excessive diffusion 
of drug, thereby kept the drug localized in the microneedles. However, when mass 
producing the needles, transfer of such viscous solution needs to be considered. Not 
only the viscous solution is harder to transfer, the solution tends to dry out quicker. 
Biologics in particular, are prone to damage by uncontrolled drying process. Based on 
these constraints, it is important to make the fabrication process flow efficiently and 
keep the polymer solution wet before the formal drying step. Drying is also crucial for 
determining the mechanical properties and structure of the microneedle matrix. 
Improper drying can cause the microneedle matrix to deform due to non-uniform 
polymeric tension when dried or degradation of the materials if exposed to improper 
temperature.     
Drying of microneedles can often be done on a batch scale. There are many 
different ways to dry microneedles. Miyano et al’s maltose dissolving microneedles 
used a melting technique at elevated temperature. In such case, no water was involved 
during their dissolving microneedle fabrication process [20]. Lee et al used centrifugal 
force to compressing carboxymethyl cellulose (CMC) microneedles while drying at 
37°C over hours [23]. The spinning provided air ventilation as well as compression 
force to prevent deformation of the polymer needles upon drying. The more 
concentrated the polymer solution, the less time is required to dry. However, the 
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drying time and drying condition can be formulation dependent.  For example, many 
sugars such as trehalose and sucrose have good water retention properties. 
Formulations containing those excipients will require a longer time to dry, possibly 
requiring an elevated temperature. In this study, the polymer blend PVA/PVP could be 
dried at room temperature over night, or with the assistance of vacuum to shorten the 
drying time. In the case of the PVA/sucrose blend used for encapsulating vaccine, 
freeze-dry (lyophilization) is recommended to avoid thermal damage to the vaccine. 
Although freeze-dry is a time-consuming process, batch drying can be done to 
achieve higher yield. 
         
7.2  Parameters for Uniform and Consistent Microneedle Insertion and 
Delivery to Skin 
 
Microneedle insertion determines the consistency of delivery and total delivered 
dose. The parameters involved in microneedle insertion include the aspect ratio of the 
needle, the spacing from needle-to-needle, the geometry of the needles, and the 
overall size of the needle array. If microneedle’s aspect ratio is too low, meaning the 
needle has a wide base relative to its height, the needle will not be able to penetrate 
the skin fully due to skin deflection. In contrast, if the aspect ratio is too high, the 
needle, especially dissolving microneedle, may break before inserting into the skin. 
The extreme case of these two situations can cause all-or-none inconsistent delivery. 
The needle-to-needle spacing would determine how much force is pushing against a 
given area. If the needles are packed too close to each other, the skin would see the 
needles as a single entity and deflect accordingly (i.e. like the “bed of nails” effect). 
Needles located far apart from each other can help overcome the skin deflection, but 
the number of needles may be limited for a given array size. Geometry of needles also 
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plays a critical role in insertion. Pyramidal needles have shown stronger mechanical 
strength than conical needles with comparable dimensions [23]. It is clear that 
stronger needles would produce more consistent delivery with less mechanical 
failures. Finally, the overall size of needle array is important to the uniformity of 
insertion on the skin. Even though a human has a relatively large skin surface area, 
skin curvature still exists in many regions. An array that is too large can result in 
partial insertion of the needle array into the skin. Even if the backing is flexible and is 
able to conform against the skin curvature, most insertion requires the needles to 
penetrate perpendicularly to the skin surface. 
 
7.3  Formulations for Desired Delivery Profile and Stability of 
Biopharmaceuticals 
 
Dissolving microneedles typically consists of excipients including binders, fillers 
or a mix of both. In general, binders are long chain polymers that provide viscosity, 
binding property to other excipients and mechanical strength to the microneedles. The 
binders are relatively less water-soluble, become swollen when in contact with water, 
or sometimes form into a gel. Thus, they are often used for slow or controlled drug 
release. Dissolvable fillers typically are very water soluble. They can be prepared into 
a highly concentrated solution or even over-saturate the solution. They are useful in 
filling the space and forming the shape of microneedles to offset the constraints of 
binder’s high viscosity. Since they readily dissolve in water or other organic solvent, 
they expedite the release of drug. Examples of fillers include trehalose, maltose, 
sucrose, dextran and dextrin, and so on. Therefore, we can achieve a desirable 
dissolution rate and release profile by adjusting the ratio of binders and fillers in a 
given formulation. 
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Fillers such as the sugar family have proven roles in stabilizing biological 
molecules. An extensive literature has shown that these fillers (stabilizers) protect the 
proteins from freezing stress and other thermal damage [112-114]. Although the exact 
mechanisms of stabilizing biological molecules by the stabilizers are not fully 
validated at this point, we found the sugars are useful in serving dual functions for 
microneedles as fillers and stabilizers. 
 
7.4  Immunization of Animal Models using Microneedles 
 
To choose an animal model for assessing microneedle delivery, we need to 
consider two main factors: skin property of the animal and measurable physiological 
or immune responses. To mimic human skin, animal skin should be anatomically 
similar. Ideally, the skin should have similar thickness of stratum corneum, epidermis, 
dermis and even the subcutaneous fatty tissue. The skin should also have similar 
elasticity and cellular composition. When performing a microneedle insertion, the 
insertion site on the skin should be hairless, or thoroughly depilated without causing 
any damage to the skin.     
In this project, we used mice as our primary animal model for immunization.  
The advantages of using mice are: (i) Plenty of experience and data already exist. (ii) 
Relatively cheap in terms of the animal cost, caging and living expense. (iii) Mice can 
be challenged by mouse-adapted influenza virus. The main disadvantages of using 
mice are: (i) Mice are too small with limited available skin surface. As a result, it is 
difficult to apply a microneedle array onto the skin properly. (ii) Mouse skin is too 
deformable. Lack of skin tension can lead to excessive skin deflection upon insertion.   
Other animal models such as pigs, ferrets and guinea pigs have their own pros 
and cons. High cost, and lack of facility and prior experience dealing with the animals 
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are the major obstacles for choosing those animal models. There is no single ideal 
animal model for preclinical studies, but to this point we have collected some 
important data and tested our hypotheses based on our animal model, mice.          
  
7.5  Future Directions of Dissolving Microneedles 
 
The key advantage of dissolving microneedles is the ability of the needle tips to 
dissolve and become non-sharp after use. In this project, the newly introduced 
arrowhead microneedles has added features to the conventional dissolving polymer 
microneedles enabling full needle insertion into the skin and rapid delivery. However, 
the current arrowhead microneedles fabricated in this project still rely on 
non-degradable components – the metal shafts and backing. Although the dull shafts 
may not be considered as biohazardous sharps, the accumulation of the waste is still 
an environmental burden that needs to be addressed. In addition, the bending of the 
metal shafts out-of-plane is an extremely tedious step to the fabrication process if 
done manually. The imprecision of bending the shafts can also lead to misalignment 
of the shafts to the polymer tips. To take a step closer to mass manufacturing and to 
benefit the environment, the shafts can be made by molding technique using 
degradable materials such as resins or ceramics. Although the use of degradable 
materials can be environmental friendly, the mechanical properties of those materials 
have to be carefully evaluated. 
Another topic to be addressed regarding dissolving microneedles is the size and 
the number of needles required for delivery. Larger needle size can encapsulate more 
drugs and thus require fewer needles and smaller skin area. However, bulkier needles 
can be difficult to insert and may require additional length to overcome the skin 
deflection. Such enhancement of needle size may also be associated with greater pain 
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[145]. Although smaller needles encapsulate less drug per needle, they are easier to 
insert. Larger dose can be achieved if we increase the number of needles, but the 
overall array size may increase. If the array gets too large, human skin curvature may 
pose a challenge for achieving a uniform insertion of the microneedle array. Since 
microneedle array does not have to be a square or polygon as seen in many existing 
prototypes, the shape and size of the array can be tailored to fit the chosen skin area 






As an alternative tool to hypodermic needles, dissolving microneedles have been 
shown to deliver drug and vaccine effectively into the skin. This project covers abroad 
scope of dissolving microneedles from fabrication to preclinical study. Conclusions 
from each study are summarized below:   
 
8.1  Controlled Drug Loading and Encapsulation in Dissolving Microneedles 
 
The goal was to develop dissolving microneedle fabrication process and design 
for improved drug delivery into skin. We have shown that higher skin bioavailability 
can be achieved by (i) localizing drug in the microneedle tip, (ii) increasing the 
amount of drug loaded in microneedles while minimizing wastage, and (iii) inserting 
microneedles more fully into the skin. Specific findings are listed below:  
 
 Highly concentrated polymer solution used as the microneedle matrix allowed 
better drug localization in the microneedle tips during casting and drying steps. 
 When only dilute polymer solution could be prepared due to viscosity constraints, 
a novel technique that involves creating bubbles in the base of microneedles 
could keep the drug localized in the needle tips.    
 Localization of drug in microneedle tip was one of the key factors that 
determined delivery efficiency to the skin. The more localized the drug was in 
the tip, the higher the delivery efficiency. Diffusion of drug into the backing 
resulted in poor delivery efficiency. 
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 By loading the drug only into the microneedles but not in the backing, the 
amount of loaded drug (the dose) could be accurately estimated. This method of 
drug loading maximized the delivery efficiency while minimizing drug wastage. 
The additional volume offered by the pedestal allowed greater drug loading into 
the microneedles. 
 The incorporation of a pedestal onto the base of the microneedle allowed the 
needle to insert more fully into the skin. As a result of more complete insertion, 
the needles dissolved faster within the skin and more drug was delivered. 
 
8.2  Development of Arrowhead Microneedles for Rapid Cutaneous Delivery 
 
To deliver drugs more efficiently and insert needle tips more completely into 
skin, we modified the pyramidal dissolving microneedle design into arrowhead 
microneedles. Arrowhead microneedles could fully embed the needle tips within the 
skin. Upon insertion, the needle tips either dissolved or mechanically separated from 
the shafts and backing. Similar to the pyramidal dissolving microneedles, the sharp 
arrowhead microneedle tips could also dissolve and leave no biohazardous sharp 
waste after use. Specific findings are listed below: 
 
 Arrowhead microneedles increased the aspect ratio of dissolving microneedles 
without compromising the mechanical properties. 
 To overcome variable skin thickness or target different regions within the skin, 
arrowhead microneedles could penetrate to various insertion depths by varying 
the shaft length.    
 Arrowhead microneedles allowed complete insertion of the needle tips into skin 
and then released the drug within. The drug could be delivered by dissolving the 
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tips within the skin or by mechanical separation of the tips from the shafts. Both 
mechanisms of delivery resulted in high delivery efficiency on a scale of seconds 
in porcine cadaver skin. 
 Drug delivery using arrowhead microneedles carrying biodegradable (i.e. 
non-dissolving) tips could achieve controlled release. The mechanical separation 
of the tips from the shafts allowed implantation of the biodegradable tips within 
the skin in seconds while the backing was removed soon after administration. 
 Arrowhead microneedles produced no sharp waste after use. Upon insertion, the 
needle’s sharp tips were dissolved or embedded within the skin, leaving behind 
the dull shafts.  Reapplying the dull shafts caused no apparent damage to the 
skin.    
 
8.3  Stability of Influenza Vaccine Encapsulated in Dissolving Microneedles 
 
The goal of this study was to encapsulate influenza vaccine in dissolving 
microneedles for transcutaneous delivery while maintaining the vaccine stability 
during and post microneedle processing. We evaluated the stability of the 
encapsulated vaccine based on hemagglutination (HA) potency, antigenicity of 
hemagglutinin and virus morphology. We found that vaccine processed into 
microneedles was more stable compared to unprocessed vaccine in solution. Specific 
findings are listed below: 
   
 Among the three microneedle drying methods: lyophilization, thermal dry at 
25°C and thermal dry at 45°C over night, lyophilization was the best method in 
maintaining the HA potency. 
 The presence of sucrose in the formulation (i.e. polymer solution used for 
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microneedle matrix) helped maintained the HA potency dramatically. Without 
sucrose, polyvinyl alcohol in the formulation alone led to a significant HA 
potency loss.  
 Encapsulated influenza vaccine processed into solid microneedles maintained 
HA potency for at least one month independent of storage temperature. 
 Unprocessed influenza vaccine in solution was stable at 4°C but lost the HA 
activity dramatically within days at 25°C, 37°C, and 45°C. 
 The HA potency of vaccine encapsulated in microneedles was independent of 
packaging condition used in this study for at least two months at 25°C. 
 For two-week storage, the vaccine encapsulated in microneedles was able to 
maintain the HA’s antigenic property at 4°C, 25°C, 37°C and 45°C while the 
unprocessed vaccine stored at 25°C, 37°C and 45°C lost nearly all HA’s 
antigenic property. 
 For two-week storage, the vaccine encapsulated in microneedles maintained its 
virus particle morphology at 4°C, 25°C, 37°C and 45°C while the unprocessed 
vaccine stored at 25°C, 37°C and 45°C showed ruptured particles or virus debris 
under electron microscopy. 
 
8.4  Protection against Lethal Virus Challenge in Immunized Mice using 
Arrowhead Microneedles 
 
After optimizing drug loading and encapsulation, delivery to the skin, and 
stability of the vaccine, we aimed to evaluate in vivo immunization of mice using 
arrowhead microneedles encapsulating influenza vaccine. The immunized mice were 
challenged by homologous influenza virus PR8 and heterologous virus WSN. The 
results showed that cutaneous immunization by arrowhead microneedles protected the 
 132
mice against lethal influenza virus challenge. Specific findings are listed below: 
 
 Antibody responses induced by arrowhead microneedle encapsulating PR8 were 
statistically indistinguishable from the intramuscular injection (Student’s t-test, 
p>0.05). 
 Hemagglutination inhibition titer levels were directly correlated with the levels 
of the antibody responses.  
 Intramuscular injection of reconstituted solution of arrowhead microneedles 
produced equivalent antibody responses and hemagglutination inhibition titer 
levels to intramuscular injection of unprocessed vaccine. This finding showed 
that the microneedle processing did not cause significant damage to the vaccine. 
 All mice immunized by microneedles showed similar weight loss to mice 
immunized by intramuscular injection. 
 All mice immunized by microneedles and intramuscular injection were protected 
from the homologous lethal virus challenge. 
 Four out of six mice immunized by microneedles were protected while all mice 
immunized by intramuscular injection were protected from the heterologous 






This project covers many fundamental aspects of drug and vaccine delivery 
using microneedles, including dissolving microneedle fabrication processes, in vitro 
evaluation of needle insertion, stability of encapsulated vaccine and in vivo 
immunization. To bring this technology closer to human clinical trial and the market, 
additional plans are recommended as follows.   
 
9.1  Optimization of Microneedle Geometry and Design for Clinical Application 
 
This project involves several modifications of microneedle geometry.  
Examples of microneedle structural change include the addition of pedestal, 
incorporation of a bubble in the needle base and mounting of shafts to form 
arrowheads. These geometrical changes led to improvement to drug delivery. For 
instance, pedestal needles allowed greater loading of drug while keeping the drug 
wastage low. Elongation of microneedles by adding pedestals also generated deeper 
insertions into the skin, which in turn led to higher delivery efficiency. Although 
conical and pyramidal microneedles have been fabricated and evaluated in some 
literature [18, 19, 22, 23, 63, 140, 144], more studies are needed to address the 
correlation between geometry and aspect-ratio on needle mechanical property and 
insertion into the skin. Optimization of microneedle geometry is important because 
appropriate geometry and needle size could facilitate insertion with minimal pain, 
cause minimal skin deflection, avoid mechanical failure of needles, and possess 
extensive drug loading capacity. All of these parameters are critical for feasible 
self-administration and reproducible clinical practice 
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9.2  In Vivo Stability Assessment of Vaccine Encapsulated in Microneedles 
 
The stability of influenza vaccine has been evaluated using in vitro assays 
including HA assay, capture ELISA and TEM. The encapsulated vaccine microneedle 
samples and unprocessed vaccine solutions have been stored at different temperatures 
under different packaging conditions. We found that the encapsulated vaccine 
maintained its morphology, hemagglutination activity and HA antigenic property over 
extend periods of time while unprocessed vaccine was very vulnerable to temperature 
variation. The next step would be to evaluate both encapsulated vaccine samples and 
unprocessed vaccine in vivo. The animal models used for this study should be able to 
generate assessable immune responses and be susceptible to lethal virus challenge. 
 
9.3  In Vivo Vaccination of Different Animal Models 
 
While all studies conducted here used mice as the animal model, future studies 
should expand to other animal models. Although using mice has the advantages of 
leveraging the established data and experience, the size and the skin properties of 
mice made needle array insertion very difficult. Therefore, animals that have 
appropriate size and similar skin property to human skin like guinea pigs, ferrets or 
pigs are worth evaluating.   
From the delivery perspective, one-minute dissolution-based immunization using 
arrowhead microneedles had now been done in mice. The other delivery mechanism 
based on mechanical separation (i.e. shearing) should also be evaluated in vivo. This 
one-second delivery aided by shear force can be very beneficial to mass vaccination 
campaign in which time is an important concern. In sum, a careful plan for 
establishing new animal models for immunization will bring the technology closer to 
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